<html lang="en" class="pb-page js" data-request-id="94d6ac5dd00901ab-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6ac5dd00901ab-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/mzXXG3UKCiv3RrvC170W-BwguWGNUbblVtTifXJGLZJhZ-3CiaZ_wyoTji-XDbygJLLaYeK4cRUJwVk_qj0gVQ=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>Milvexian for the Prevention of Venous Thromboembolism | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6ac5dd00901ab-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.4761340670505936"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Orthopedics General|Anticoagulation/Thromboembolism (Cardiology)|Surgery General|Coagulation">
<meta name="Specialties" content="Hematology/Oncology|Cardiology|Pulmonary/Critical Care|Orthopedics|Surgery"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2113194","title":"Milvexian for the Prevention of Venous Thromboembolism","category":"Research","type":"Original Article","topics":"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Orthopedics General|Anticoagulation/Thromboembolism (Cardiology)|Surgery General|Coagulation","specialties":"Hematology/Oncology|Cardiology|Pulmonary/Critical Care|Orthopedics|Surgery","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-12-02T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Anticoagulation/Thromboembolism (Pulmonary/Critical Care)|Orthopedics General|Anticoagulation/Thromboembolism (Cardiology)|Surgery General|Coagulation\"/\u003e\n\u003cmeta name\u003d\"Specialties\" content\u003d\"Hematology/Oncology|Cardiology|Pulmonary/Critical Care|Orthopedics|Surgery\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2113194","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6ac5dd00901ab-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="Milvexian for the Prevention of Venous Thromboembolism"><meta name="dc.Creator" content="Jeffrey I. Weitz"><meta name="dc.Creator" content="John Strony"><meta name="dc.Creator" content="Walter Ageno"><meta name="dc.Creator" content="David Gailani"><meta name="dc.Creator" content="Elaine M. Hylek"><meta name="dc.Creator" content="Michael R. Lassen"><meta name="dc.Creator" content="Kenneth W. Mahaffey"><meta name="dc.Creator" content="Ravi S. Notani"><meta name="dc.Creator" content="Robin Roberts"><meta name="dc.Creator" content="Annelise Segers"><meta name="dc.Creator" content="Gary E. Raskob"><meta name="dc.Description" content="Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are..."><meta name="Description" content="Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-12-02"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2113194"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202112023852310"><meta name="dc.Language" content="EN"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2113194">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2113194">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2113194">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="Milvexian for the Prevention of Venous Thromboembolism | NEJM">
        <meta property="og:title" content="Milvexian for the Prevention of Venous Thromboembolism | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2113194">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/a7da21f0-142e-4174-931b-00e602025cf9/nejmoa2113194_f1.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/a7da21f0-142e-4174-931b-00e602025cf9/nejmoa2113194_f1.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism
may be more effective and result in less bleeding than conventional anticoagulants.
Additional data are...">
        <meta name="twitter:description" content="Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism
may be more effective and result in less bleeding than conventional anticoagulants.
Additional data are...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="1997">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2113194">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2113194">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;issue:issue:doi\:10.1056/nejm_2021.385.issue-23;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:doi\:10.1056/NEJMoa2113194;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><meta http-equiv="P3P" content="CP=&quot;NOI DSP ADM OUR IND OTC&quot;"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2113194" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2113194" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2113194" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2113194" class="inputDoi"><input type="hidden" value="J.I. Weitz and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:2161-2172" class="inputCitation"><input type="hidden" value="11-15-2021" class="inputEPubDate"><input type="hidden" value="December 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="Milvexian for the Prevention of Venous Thromboembolism" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6ac5dd00901ab-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">Milvexian for the Prevention of Venous Thromboembolism</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Jeffrey I.</span> <span property="familyName">Weitz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">John</span> <span property="familyName">Strony</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Walter</span> <span property="familyName">Ageno</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">David</span> <span property="familyName">Gailani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elaine M.</span> <span property="familyName">Hylek</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Michael R.</span> <span property="familyName">Lassen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Kenneth W.</span> <span property="familyName">Mahaffey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Ravi S.</span> <span property="familyName">Notani</span>, <span property="honorificSuffix">M.B.A.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Robin</span> <span property="familyName">Roberts</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Annelise</span> <span property="familyName">Segers</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Gary E.</span> <span property="familyName">Raskob</span>, <span property="honorificSuffix">Ph.D.</span></span>, for <span property="author" typeof="Person" role="listitem">the AXIOMATIC-TKR Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">November 15, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">2161</span>-<span property="pageEnd">2172</span></div><div class="doi">DOI: 10.1056/NEJMoa2113194</div><div class="core-enumeration"><a href="/toc/nejm/385/23"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">23</span></span></a></div><div><a href="#tab-information">Copyright Â© 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJeffrey%2BI.%2BWeitz%252C%2BJohn%2BStrony%252C%2BWalter%2BAgeno%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D23%26contentID%3D10.1056%252FNEJMoa2113194%26title%3DMilvexian%2Bfor%2Bthe%2BPrevention%2Bof%2BVenous%2BThromboembolism%26publicationDate%3D12%252F02%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2113194" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DJeffrey%2BI.%2BWeitz%252C%2BJohn%2BStrony%252C%2BWalter%2BAgeno%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D23%26contentID%3D10.1056%252FNEJMoa2113194%26title%3DMilvexian%2Bfor%2Bthe%2BPrevention%2Bof%2BVenous%2BThromboembolism%26publicationDate%3D12%252F02%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/9ca08fcd-bb33-4e22-9fc0-9bd0955e26c4/nejmoa2113194.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2113194.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2113194" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2113194" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2113194.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Factor XIa inhibitors for the prevention and treatment of venous and arterial thromboembolism may be more effective and result in less bleeding than conventional anticoagulants. Additional data are needed regarding the efficacy and safety of milvexian, an oral factor XIa inhibitor.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this parallel-group, phase 2 trial, we randomly assigned 1242 patients undergoing knee arthroplasty to receive one of seven postoperative regimens of milvexian (25 mg, 50 mg, 100 mg, or 200 mg twice daily or 25 mg, 50 mg, or 200 mg once daily) or enoxaparin (40 mg once daily). The primary efficacy outcome was venous thromboembolism (which was a composite of asymptomatic deep-vein thrombosis, confirmed symptomatic venous thromboembolism, or death from any cause). The principal safety outcome was bleeding.</div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">Among the patients receiving milvexian twice daily, venous thromboembolism developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg. Among those receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg, as compared with 54 of 252 patients (21%) taking enoxaparin. The doseâresponse relationship with twice-daily milvexian was significant (one-sided P&lt;0.001), and the 12% incidence of venous thromboembolism with twice-daily milvexian was significantly lower than the prespecified benchmark of 30% (one-sided P&lt;0.001). Bleeding of any severity occurred in 38 of 923 patients (4%) taking milvexian and in 12 of 296 patients (4%) taking enoxaparin; major or clinically relevant nonmajor bleeding occurred in 1% and 2%, respectively; and serious adverse events were reported in 2% and 4%, respectively.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">Postoperative factor XIa inhibition with oral milvexian in patients undergoing knee arthroplasty was effective for the prevention of venous thromboembolism and was associated with a low risk of bleeding. (Funded by Bristol Myers Squibb and Janssen Research and Development; AXIOMATIC-TKR ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03891524" target="_blank">NCT03891524</a>.)</div></section></section></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Oral anticoagulants are a mainstay for the prevention and treatment of venous and arterial thromboembolism. Although direct oral anticoagulants have replaced vitamin K antagonists for many indications, bleeding remains the major side effect. Fear of bleeding contributes to the underuse of anticoagulants in eligible patients with atrial fibrillation and to the inappropriate use of low-dose direct oral anticoagulant regimens.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2" id="body-ref-r2" href-manipulated="true">1,2</a></sup> Therefore, the need for safer oral anticoagulants persists.</div><div role="paragraph">Factor XI is a promising target for the development of safer anticoagulants because it is an important driver of thrombus growth but plays a subsidiary part in hemostasis.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-1" href-manipulated="true" aria-label="Reference 3">3</a></sup> Thus, patients with congenital factor XI deficiency are at lower risk for venous thromboembolism and ischemic stroke than those with normal factor XI levels but rarely have spontaneous bleeding.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5 r6" id="body-ref-r6" href-manipulated="true">4-6</a></sup></div><div role="paragraph">The development of new anticoagulants usually starts with dose-finding studies involving patients undergoing elective knee arthroplasty, because efficacy can be objectively and efficiently assessed by using venography to determine the incidence of deep-vein thrombosis after surgery. In such patients, preoperative subcutaneous administration of an antisense oligonucleotide that reduces factor XI levels or postoperative factor XI inhibition with intravenous abelacimab, a factor XIâdirected antibody, was superior to enoxaparin for the prevention of venous thromboembolism.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-1" href-manipulated="true">7,8</a></sup></div><div role="paragraph">Milvexian is a selective factor XIa inhibitor that is rapidly absorbed after oral administration and has a half-life of approximately 12 hours.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> In this proof-of-principle phase 2 trial (Antithrombotic Treatment with Factor XIa Inhibition to Optimize Management of Acute Thromboembolic Events in Total Knee Replacement [AXIOMATIC-TKR]), we compared the efficacy and safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Design and Oversight</h3><div role="paragraph">We used a randomized, parallel-group, adaptive design with blinded outcome adjudication to compare milvexian with enoxaparin. The trial was open label for treatment assignment to milvexian or enoxaparin, but patients and observers (trial personnel and assessors of outcomes) were unaware of the milvexian dose regimen.</div><div role="paragraph">An operations committee and a steering committee were responsible for the design and oversight of the trial, in collaboration with the sponsors (Bristol Myers Squibb and Janssen Research and Development). The sponsors were responsible for data collection, maintenance, and analysis. The institutional review board at each participating center approved the <a href="#ap1">protocol</a>, which is available with the full text of this article at NEJM.org. All the patients provided written informed consent.</div><div role="paragraph">The members of the steering committee were unaware of the treatment assignments. The operations committee, whose members were aware of the treatment assignments, periodically reviewed trial outcomes and adverse events for safety oversight and, with guidance from predefined criteria for insufficient efficacy or excessive bleeding, made recommendations to the steering committee to continue the trial unchanged or to discontinue or add milvexian dose regimens.</div><div role="paragraph">An independent clinical-events committee whose members were unaware of the treatment assignments adjudicated all venograms for the presence and extent of deep-vein thrombosis, all suspected episodes of symptomatic venous thromboembolism or bleeding, and all deaths. The first, second, and last authors wrote the first draft of the manuscript with subsequent input from the other authors. No one who is not an author contributed to the writing of the manuscript. The authors vouch for the completeness and accuracy of the data and for the fidelity of the trial to the protocol.</div></section><section id="sec-1-2"><h3>Patients</h3><div role="paragraph">Patients undergoing elective unilateral total knee arthroplasty were eligible if they were 50 years of age or older, had a medically stable condition, and were appropriate candidates for anticoagulant prophylaxis. The main exclusion criteria were contraindications to enoxaparin (e.g., creatinine clearance, &lt;30 ml per minute), a history of severe hepatic impairment or previous venous thromboembolism, the use of long-term antithrombotic therapy other than aspirin (â¤100 mg per day), or the inability to undergo venography. The full list of inclusion and exclusion criteria is provided in the protocol.</div></section><section id="sec-1-3"><h3>Randomization and Trial Treatment</h3><div role="paragraph">An adaptive design was used to improve patient recruitment for the doseâresponse evaluation. Initially, eligible patients were randomly assigned, in a 1:1:1:1:1:1:2 ratio, to one of seven parallel treatment groups, which included four twice-daily milvexian regimens (25 mg, 50 mg, 100 mg, or 200 mg), two once-daily milvexian regimens (25 mg or 200 mg), and enoxaparin (40 mg once daily), respectively. Randomization was performed postoperatively with the use of a centralized interactive Web-based response system and was stratified according to the geographic region of the trial centers. Patients in the milvexian groups were asked to take a total of four capsules (active drug or matching placebo) per day, two capsules in the morning and two capsules in the evening. In the enoxaparin group, the drug was administered subcutaneously at a dose of 40 mg once daily. Trial medication was started 12 to 24 hours after surgery. A single dose of subcutaneous enoxaparin was allowed the evening before surgery according to the local standard of care. Treatment with milvexian or enoxaparin was given for 10 to 14 days after surgery.</div><div role="paragraph">The operations committee performed one ad hoc and one prespecified interim analysis. As a result of the ad hoc analysis, which occurred when 252 patients had undergone randomization, enrollment into the group receiving 25 mg of milvexian once daily was stopped because the point estimate for the incidence of venous thromboembolism was 25%, which met the prespecified criteria for insufficient efficacy. A regimen of 50 mg of milvexian once daily was then added to gain more information about the efficacy and safety of once-daily as compared with twice-daily milvexian dosing. On the basis of the results of the prespecified interim analysis, which was undertaken when at least 50 patients with a venogram that could be evaluated or with a confirmed symptomatic event were enrolled in each of the twice-daily milvexian groups, the randomization ratio was modified to enable recruitment of approximately 150 patients into the group receiving 50 mg of milvexian once daily.</div></section><section id="sec-1-4"><h3>Trial Outcomes</h3><div role="paragraph">The primary efficacy outcome was venous thromboembolism, which was a composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10 to 14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death from any cause. Unilateral venography that is performed only on the operated leg detects more than 90% of deep-vein thromboses in patients undergoing unilateral knee arthroplasty and reduces discomfort and the risk of allergic reactions or kidney damage from the contrast material.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r10" id="body-ref-r10-1" href-manipulated="true">7,10</a></sup></div><div role="paragraph">The major secondary efficacy outcomes were proximal deep-vein thrombosis (symptomatic or asymptomatic), distal deep-vein thrombosis (symptomatic or asymptomatic), nonfatal pulmonary embolism, and death. An exploratory efficacy outcome was the extent of venous thrombosis on venography, which was assessed by the adjudication committee with the use of predefined categories.</div><div role="paragraph">The principal safety outcome was bleeding of any severity, which was defined as the composite of major bleeding, clinically relevant nonmajor bleeding, and minimal bleeding. Secondary safety outcomes were major bleeding, clinically relevant nonmajor bleeding, clinically relevant bleeding (defined as the composite of major bleeding and clinically relevant nonmajor bleeding), and minimal bleeding. Bleeding was classified as major if it was overt and was associated with a decrease in the hemoglobin level of 2 g per deciliter or more or resulted in transfusion of 2 or more units of blood with a temporal association within 24 to 48 hours of the bleeding episode, or if it occurred in a critical area or organ or contributed to death. Bleeding at the surgical site was defined as major only if it warranted intervention; caused hemodynamic instability; or caused hemarthrosis that delayed mobilization or wound healing and resulted in prolonged hospitalization or deep wound infection. Overt bleeding that did not meet the criteria for major bleeding, but that warranted medical examination or intervention or had clinical consequences, was classified as clinically relevant nonmajor bleeding. Bleeding that did not meet the criteria for major or clinically relevant nonmajor bleeding was classified as minimal bleeding.<sup><a href="#core-r11" role="doc-biblioref" data-xml-rid="r11" id="body-ref-r11" href-manipulated="true" aria-label="Reference 11">11</a></sup></div></section><section id="sec-1-5"><h3>Surveillance and Follow-up</h3><div role="paragraph">Patients were evaluated preoperatively within 30 days before surgery, at the time of randomization, and after surgery on day 1, days 4 and 7 (if patients were still hospitalized), days 10 to 14, and at 6 weeks (Â±10 days). Patients were instructed to report symptoms suggestive of venous thromboembolism or bleeding.</div></section><section id="sec-1-6"><h3>Laboratory Measurements</h3><div role="paragraph">The activated partial-thromboplastin time and prothrombin time were measured in a central laboratory with the use of Actin FS and Innovin, respectively (Siemens Healthcare). The activated partial-thromboplastin time ratio and prothrombin time ratio for each patient were calculated by dividing postoperative values by those measured preoperatively.</div></section><section id="sec-1-7"><h3>Statistical Analysis</h3><div role="paragraph">The primary hypothesis was that milvexian would reduce the risk of venous thromboembolism during the 10-to-14-day treatment period, thereby establishing proof of efficacy. The criteria for proof of efficacy were defined a priori as either a significant doseâresponse trend with the twice-daily milvexian regimens or an incidence of venous thromboembolism with the combined twice-daily milvexian regimens that was significantly lower than 30%. A postoperative incidence of venous thromboembolism of 30% was chosen as a conservative estimate of the incidence without thromboprophylaxis in patients undergoing knee arthroplasty.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-2" href-manipulated="true" aria-label="Reference 10">10</a></sup> The primary efficacy outcome focused on twice-daily milvexian regimens because with a half-life of approximately 12 hours, milvexian is suitable for twice-daily dosing. A prespecified multiplicity correction was applied for the testing of the two components of the primary hypothesis; the familywise error rate was controlled at a one-sided alpha level of 0.1, with a one-sided alpha level of 0.05 assigned to each component, to have more than 99% power to declare proof of efficacy.</div><div role="paragraph">The planned sample was 900 patients, with an option to increase the sample to approximately 1200 patients depending on the results of the interim analysis or the percentage of patients with venograms that could not be evaluated. We calculated that the trial would have at least 99% power to show proof of efficacy with a one-sided alpha level of 5% if 80% or more of enrolled patients could be evaluated for efficacy and if the incidence of venous thromboembolism ranged from 18% with the lowest twice-daily regimen of milvexian to 11% with the highest twice-daily regimen. It was also prespecified that the efficacy of the highest-dose regimen of milvexian with acceptable safety would be compared with that of enoxaparin. This comparison was estimated to have at least 90% power with a one-sided alpha level of 5%.</div><div role="paragraph">The primary analysis for efficacy was performed in the modified intention-to-treat population, which included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. Because deep-vein thrombosis after knee arthroplasty is often asymptomatic, the confirming or ruling out of thrombosis requires a venogram that can be evaluated. The incidence of venous thromboembolism in the combined groups receiving milvexian twice daily was compared with the 30% benchmark with the use of the exact binomial test. Evidence for a doseâresponse trend with the twice-daily milvexian regimens was evaluated with the multiple comparison procedures and modeling (MCP-Mod) framework with the use of prespecified models (see the statistical analysis plan, available with the protocol at NEJM.org).<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup> For analysis of the major secondary efficacy outcomes, the CochranâMantelâHaenszel method with trial region as a stratification factor was used to calculate the risk ratio and the corresponding confidence interval for each milvexian group relative to the enoxaparin group, and two-sided testing was used to compare individual milvexian dose regimens with enoxaparin.</div><div role="paragraph">Analysis of safety outcomes was performed in the safety population, which included all the patients who had undergone randomization and had received at least one dose of a trial medication; the time for analysis included the on-treatment period plus 2 days. For each bleeding outcome, the incidence in each milvexian group was compared with that in the enoxaparin group with the same methods used for evaluation of the secondary efficacy outcomes. The KaplanâMeier method was used to assess the time to the first occurrence of any bleeding with milvexian or enoxaparin.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From June 27, 2019, through February 25, 2021, a total of 1242 patients underwent randomization at 118 centers in 18 countries. The analysis populations are provided in <a href="#f1">Figure 1</a>; all the patients were followed for 30 days. The characteristics of the patients at baseline were similar across the trial groups (<a href="#t1">Table 1</a>). Treatment adherence as assessed by counting pills or enoxaparin syringes was 80% or higher in 95% of randomly assigned patients, and 75% of randomly assigned patients were 100% adherent.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f1.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/a7da21f0-142e-4174-931b-00e602025cf9/assets/images/large/nejmoa2113194_f1.jpg" height="1997" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Enrollment, Randomization, and Populations for Analyses.</div><div class="notes"><div role="doc-footnote">Enrollment in the group receiving 25 mg of milvexian once daily was stopped early by the trial operations committee after an ad hoc analysis showed insufficient efficacy. A regimen of 50 mg of milvexian once daily was then added to the trial regimens. One patient who was assigned to receive 100 mg of milvexian twice daily received 50 mg twice daily, and another patient who was assigned to receive 200 mg of milvexian twice daily received 25 mg once daily. For the safety analyses, these patients were included in the actual treatment group, whereas for the efficacy analyses, they were included in the planned treatment group.</div></div></figcaption></figure></div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t1.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/2b7d5093-0f12-4547-bdb5-5cb0a3a70fa0/assets/images/large/nejmoa2113194_t1.jpg" height="3438" width="1804" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<a href="#t1fn2" role="doc-noteref">â </a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg</th><th class="xxxx-borders">50 mg</th><th class="xxxx-borders">100 mg</th><th class="xxxx-borders">200 mg</th><th class="xxxx-borders">25 mg</th><th class="xxxx-borders">50 mg</th><th class="xxxx-borders">200 mg</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Modified intention-to-treat population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">129</td><td class="xxxx-borders">124</td><td class="xxxx-borders">134</td><td class="xxxx-borders">131</td><td class="xxxx-borders">28</td><td class="xxxx-borders">127</td><td class="xxxx-borders">123</td><td class="xxxr-borders">252</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age â yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">69</td><td class="xxxx-borders">68</td><td class="xxxx-borders">67</td><td class="xxxx-borders">69</td><td class="xxxx-borders">67</td><td class="xxxx-borders">68</td><td class="xxxx-borders">68</td><td class="xxxr-borders">68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">51â87</td><td class="xxxx-borders shading">51â87</td><td class="xxxx-borders shading">50â86</td><td class="xxxx-borders shading">50â86</td><td class="xxxx-borders shading">55â77</td><td class="xxxx-borders shading">50â88</td><td class="xxxx-borders shading">50â88</td><td class="xxxr-borders shading">50â90</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex â no. (%)</td><td class="xxxx-borders">92 (71)</td><td class="xxxx-borders">89 (72)</td><td class="xxxx-borders">88 (66)</td><td class="xxxx-borders">89 (68)</td><td class="xxxx-borders">18 (64)</td><td class="xxxx-borders">92 (72)</td><td class="xxxx-borders">88 (72)</td><td class="xxxr-borders">171 (68)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">112 (87)</td><td class="xxxx-borders">107 (86)</td><td class="xxxx-borders">117 (87)</td><td class="xxxx-borders">116 (89)</td><td class="xxxx-borders">28 (100)</td><td class="xxxx-borders">103 (81)</td><td class="xxxx-borders">105 (85)</td><td class="xxxr-borders">216 (86)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">16 (12)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxx-borders shading">14 (10)</td><td class="xxxx-borders shading">14 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">21 (17)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxr-borders shading">29 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Weight â kg</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">79</td><td class="xxxx-borders shading">85</td><td class="xxxx-borders shading">84</td><td class="xxxx-borders shading">82</td><td class="xxxx-borders shading">80</td><td class="xxxx-borders shading">82</td><td class="xxxr-borders shading">81</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">40â150</td><td class="xxxx-borders">44â150</td><td class="xxxx-borders">48â130</td><td class="xxxx-borders">42â132</td><td class="xxxx-borders">56â134</td><td class="xxxx-borders">48â181</td><td class="xxxx-borders">48â129</td><td class="xxxr-borders">41â146</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Baseline creatinine clearance â ml/min<a href="#t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">86</td><td class="xxxx-borders">92</td><td class="xxxx-borders">90</td><td class="xxxx-borders">94</td><td class="xxxx-borders">95</td><td class="xxxx-borders">88</td><td class="xxxx-borders">91</td><td class="xxxr-borders">92</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">71â109</td><td class="xxxx-borders shading">75â113</td><td class="xxxx-borders shading">70â118</td><td class="xxxx-borders shading">70â114</td><td class="xxxx-borders shading">72â127</td><td class="xxxx-borders shading">70â105</td><td class="xxxx-borders shading">73â115</td><td class="xxxr-borders shading">72â114</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Preoperative enoxaparin â no. (%)</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">9 (7)</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">7 (5)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">10 (8)</td><td class="xxxx-borders">11 (9)</td><td class="xxxr-borders">28 (11)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Type of anesthesia â no. (%)<a href="#t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">General</td><td class="xxxx-borders">29 (22)</td><td class="xxxx-borders">25 (20)</td><td class="xxxx-borders">31 (23)</td><td class="xxxx-borders">34 (26)</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">29 (23)</td><td class="xxxx-borders">26 (21)</td><td class="xxxr-borders">57 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Spinal</td><td class="xxxx-borders shading">99 (77)</td><td class="xxxx-borders shading">99 (80)</td><td class="xxxx-borders shading">102 (76)</td><td class="xxxx-borders shading">96 (73)</td><td class="xxxx-borders shading">23 (82)</td><td class="xxxx-borders shading">101 (80)</td><td class="xxxx-borders shading">99 (80)</td><td class="xxxr-borders shading">194 (77)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Epidural</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (5)</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">7 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Regional</td><td class="xxxx-borders shading">20 (16)</td><td class="xxxx-borders shading">33 (27)</td><td class="xxxx-borders shading">42 (31)</td><td class="xxxx-borders shading">33 (25)</td><td class="xxxx-borders shading">6 (21)</td><td class="xxxx-borders shading">33 (26)</td><td class="xxxx-borders shading">29 (24)</td><td class="xxxr-borders shading">58 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">9 (4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Duration of surgery â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxr-borders">1.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">0.5â3.5</td><td class="xxxx-borders shading">0.7â3.1</td><td class="xxxx-borders shading">0.5â6.6</td><td class="xxxx-borders shading">0.6â2.8</td><td class="xxxx-borders shading">0.8â2.8</td><td class="xxxx-borders shading">0.6â3.3</td><td class="xxxx-borders shading">0.7â3.5</td><td class="xxxr-borders shading">0.4â3.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Tourniquet use â no. (%)</td><td class="xxxx-borders">89 (69)</td><td class="xxxx-borders">88 (71)</td><td class="xxxx-borders">98 (73)</td><td class="xxxx-borders">84 (64)</td><td class="xxxx-borders">20 (71)</td><td class="xxxx-borders">93 (73)</td><td class="xxxx-borders">84 (68)</td><td class="xxxr-borders">188 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Duration of tourniquet use â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.3</td><td class="xxxr-borders">1.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">0.3â15</td><td class="xxxx-borders shading">0.2â23</td><td class="xxxx-borders shading">0.3â10</td><td class="xxxx-borders shading">0.4â10</td><td class="xxxx-borders shading">0.2â19</td><td class="xxxx-borders shading">0.3â20</td><td class="xxxx-borders shading">0.3â15</td><td class="xxxr-borders shading">0.2â15</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Time after surgery to ambulation â days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">0â3</td><td class="xxxx-borders">0â3</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0Ì«â4</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0â6</td><td class="xxxr-borders">0â4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Baseline factor XI clotting activity â %<a href="#t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">109</td><td class="xxxx-borders">107</td><td class="xxxx-borders">104</td><td class="xxxx-borders">110</td><td class="xxxx-borders">107</td><td class="xxxx-borders">100</td><td class="xxxx-borders">102</td><td class="xxxr-borders">114</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">94â127</td><td class="xxxx-borders shading">91â119</td><td class="xxxx-borders shading">93â119</td><td class="xxxx-borders shading">95â124</td><td class="xxxx-borders shading">89â116</td><td class="xxxx-borders shading">87â117</td><td class="xxxx-borders shading">87â113</td><td class="xxxr-borders shading">100â131</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Baseline activated partial-thromboplastin time â sec<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">27</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxr-borders shading">26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">24â28</td><td class="xxxx-borders">25â29</td><td class="xxxx-borders">25â28</td><td class="xxxx-borders">24â28</td><td class="xxxx-borders">25â28</td><td class="xxxx-borders">25â29</td><td class="xxxx-borders">25â28</td><td class="xxxr-borders">25â28</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Safety population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">148</td><td class="xxxx-borders">148</td><td class="xxxx-borders">149</td><td class="xxxx-borders">148</td><td class="xxxx-borders">33</td><td class="xxxx-borders">150</td><td class="xxxx-borders">147</td><td class="xxxr-borders">296</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Time after surgery to milvexian or enoxaparin administration â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">23</td><td class="xxxr-borders">22</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">13â25</td><td class="xxxx-borders shading">12â26</td><td class="xxxx-borders shading">13â25</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">14â26</td><td class="xxxr-borders shading">7â34</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Duration of milvexian or enoxaparin treatment â days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">12</td><td class="xxxr-borders shading">12</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Range</td><td class="xbxx-borders">1â16</td><td class="xbxx-borders">2â16</td><td class="xbxx-borders">4â17</td><td class="xbxx-borders">4â16</td><td class="xbxx-borders">9â14</td><td class="xbxx-borders">6â16</td><td class="xbxx-borders">1â16</td><td class="xbxr-borders">1â15</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients.<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">The modified intention-to-treat population included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. The safety population included all the patients who had received at least one dose of a trial medication. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t1fn2" role="paragraph">Enoxaparin was administered subcutaneously at a dose of 40 mg once daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t1fn3" role="paragraph">Race was reported by the patient. Three patients in the group receiving 50 mg of milvexian once daily and two in the enoxaparin group chose not to report information on race.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="t1fn4" role="paragraph">Creatinine clearance values were calculated with the use of the Cockcroft and Gault equation.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="t1fn5" role="paragraph">Patients may have undergone more than one type of anesthesia.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="t1fn6" role="paragraph">The normal range for factor XI clotting activity is 60 to 150%.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">The normal range for the activated partial-thromboplastin time is 22 to 29 seconds.</div></div></div></figcaption></figure></div></section><section id="sec-2-2"><h3>Efficacy</h3><div role="paragraph">Venograms that could be evaluated were obtained in 1047 of 1219 patients (86%) who received a trial medication (<a href="#f1">Figure 1</a>); 127 of 923 patients (14%) in the milvexian groups and 45 of 296 patients (15%) in the enoxaparin group did not undergo venography, had venograms that could not be evaluated, or had venograms outside the prespecified time window.</div><div role="paragraph">Efficacy outcomes are provided in <a href="#t2">Table 2</a>. Among the patients receiving milvexian twice daily, venous thromboembolism (primary efficacy outcome) developed in 27 of 129 (21%) taking 25 mg, in 14 of 124 (11%) taking 50 mg, in 12 of 134 (9%) taking 100 mg, and in 10 of 131 (8%) taking 200 mg (total daily milvexian doses of 50 mg, 100 mg, 200 mg, and 400 mg, respectively). These findings are consistent with a significant doseâresponse relationship (one-sided P&lt;0.001). Venous thromboembolism developed in 63 of 518 patients (12%) given twice-daily milvexian, an incidence significantly lower than the prespecified benchmark of 30% (one-sided P&lt;0.001). Thus, both proof-of-efficacy criteria were met.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t2.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/d208a498-1156-4944-a682-5b3c7503d556/assets/images/large/nejmoa2113194_t2.jpg" height="1573" width="2615" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<br>(N=252)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg<br>(N=129)</th><th class="xxxx-borders">50 mg<br>(N=124)</th><th class="xxxx-borders">100 mg<br>(N=134)</th><th class="xxxx-borders">200 mg<br>(N=131)</th><th class="xxxx-borders">25 mg<br>(N=28)</th><th class="xxxx-borders">50 mg<br>(N=127)</th><th class="xxxx-borders">200 mg<br>(N=123)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary efficacy outcome: venous thromboembolism<a href="#t2fn2" role="doc-noteref">â </a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any event â no. (%)</td><td class="xxxx-borders">27 (21)</td><td class="xxxx-borders">14 (11)</td><td class="xxxx-borders">12 (9)</td><td class="xxxx-borders">10 (8)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">30 (24)</td><td class="xxxx-borders">8 (7)</td><td class="xxxr-borders">54 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders shading">0.97 <br>(0.65â1.45)</td><td class="xxxx-borders shading">0.53 <br>(0.31â0.90)</td><td class="xxxx-borders shading">0.42 <br>(0.23â0.76)</td><td class="xxxx-borders shading">0.37 <br>(0.19â0.69)</td><td class="xxxx-borders shading">1.00 <br>(0.51â1.97)</td><td class="xxxx-borders shading">1.15 <br>(0.78â1.70)</td><td class="xxxx-borders shading">0.30 <br>(0.15â0.62)</td><td class="xxxr-borders shading">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Components of the primary efficacy outcome â no.<a href="#t2fn3" role="doc-noteref">â¡</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Nonfatal pulmonary embolism</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Symptomatic distal deep-vein thrombosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Asymptomatic proximal deep-vein thrombosis</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Asymptomatic distal deep-vein thrombosis</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">50</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Extent of deep-vein thrombosis on venography â no.</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confluent distal into proximal</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Isolated proximal</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large: â¥10 cm</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Small: &lt;10 cm</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Isolated distal</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Extensive: â¥2 veins</td><td class="xxxx-borders">9</td><td class="xxxx-borders">5</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2</td><td class="xxxx-borders">5</td><td class="xxxx-borders">9</td><td class="xxxx-borders">1</td><td class="xxxr-borders">20</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Limited: &lt;2 veins</td><td class="xbxx-borders shading">17</td><td class="xbxx-borders shading">8</td><td class="xbxx-borders shading">9</td><td class="xbxx-borders shading">8</td><td class="xbxx-borders shading">2</td><td class="xbxx-borders shading">18</td><td class="xbxx-borders shading">7</td><td class="xbxr-borders shading">30</td></tr></tbody></table></div><figcaption><div class="caption">Efficacy Outcomes.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">Efficacy outcomes were assessed in the modified intention-to-treat population, which included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t2fn2" role="paragraph">Venous thromboembolism was a composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10 to 14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death from any cause.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="t2fn3" role="paragraph">There were no cases of symptomatic proximal deep-vein thrombosis.</div></div></div></figcaption></figure></div><div role="paragraph">Among the patients receiving milvexian once daily, venous thromboembolism developed in 7 of 28 (25%) taking 25 mg, in 30 of 127 (24%) taking 50 mg, and in 8 of 123 (7%) taking 200 mg; these findings are also consistent with a significant doseâresponse relationship (one-sided P&lt;0.001). In the enoxaparin group, venous thromboembolism developed in 54 of 252 patients (21%). The per-protocol analysis yielded similar efficacy results (Table S1 in the <a href="#ap2">Supplementary Appendix</a>).</div><div role="paragraph">One patient in the enoxaparin group died by suicide 1 day after randomization; no deaths from pulmonary embolism occurred. Three patients had symptomatic nonfatal pulmonary embolism (one in the enoxaparin group and two in the milvexian groups). The extent of thrombosis with milvexian and enoxaparin is shown in <a href="#t2">Table 2</a>.</div></section><section id="sec-2-3"><h3>Bleeding</h3><div role="paragraph">The bleeding outcomes are provided in <a href="#t3">Table 3</a>. The principal safety outcome of bleeding of any severity occurred in 38 of 923 patients (4%) given milvexian and in 12 of 296 patients (4%) given enoxaparin. Most bleeding episodes were in the minimal category and involved the surgical site. No major bleeding episodes were seen with milvexian, and one occurred with enoxaparin. The incidence of clinically relevant bleeding (the composite of major bleeding and clinically relevant nonmajor bleeding) was 1% with milvexian and 2% with enoxaparin.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t3.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/36d3dc25-a77e-46eb-ba77-cc40bcdf0a88/assets/images/large/nejmoa2113194_t3.jpg" height="1150" width="2616" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<br>(N=296)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg<br>(N=148)</th><th class="xxxx-borders">50 mg<br>(N=148)</th><th class="xxxx-borders">100 mg<br>(N=149)</th><th class="xxxx-borders">200 mg<br>(N=148)</th><th class="xxxx-borders">25 mg<br>(N=33)</th><th class="xxxx-borders">50 mg<br>(N=150)</th><th class="xxxx-borders">200 mg<br>(N=147)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any bleeding â no. (%)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxr-borders shading">12 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders">0.33 <br>(0.08â1.43)</td><td class="xxxx-borders">1.15 <br>(0.47â2.82)</td><td class="xxxx-borders">1.14 <br>(0.47â2.80)</td><td class="xxxx-borders">0.81 <br>(0.29â2.24)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">1.17 <br>(0.50â2.72)</td><td class="xxxx-borders">1.51 <br>(0.66â3.43)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major bleeding or clinically relevant nonmajor bleeding â no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">0.79 <br>(0.16â3.96)</td><td class="xxxx-borders">0.39 <br>(0.05â3.30)</td><td class="xxxx-borders">0.39 <br>(0.05â3.28)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">0.68 <br>(0.14â3.39)</td><td class="xxxx-borders">0.40 <br>(0.05â3.34)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major bleeding â no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (&lt;1)<a href="#t3fn2" role="doc-noteref">â </a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Clinically relevant nonmajor bleeding â no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event â no. (%)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">At least one adverse event â no. (%)</td><td class="xxxx-borders">56 (38)</td><td class="xxxx-borders">67 (45)</td><td class="xxxx-borders">51 (34)</td><td class="xxxx-borders">54 (36)</td><td class="xxxx-borders">7 (21)</td><td class="xxxx-borders">58 (39)</td><td class="xxxx-borders">65 (44)</td><td class="xxxr-borders">113 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of treatment â no. (%)</td><td class="xbxx-borders shading">2 (1)</td><td class="xbxx-borders shading">7 (5)</td><td class="xbxx-borders shading">2 (1)</td><td class="xbxx-borders shading">4 (3)</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">4 (3)</td><td class="xbxx-borders shading">6 (4)</td><td class="xbxr-borders shading">8 (3)</td></tr></tbody></table></div><figcaption><div class="caption">Safety Outcomes.<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">Safety outcomes were assessed in the safety population, which included all the patients who had received at least one dose of a trial medication; the time for analysis included the period during which a trial medication was administered plus 2 days. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="t3fn2" role="paragraph">The patient had a spontaneous subdural hematoma with decreased level of consciousness.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Other Safety Outcomes</h3><div role="paragraph">Adverse events with treatment were reported in 358 of 923 patients (39%) given milvexian and in 113 of 296 patients (38%) given enoxaparin, whereas serious adverse events were reported in 2% and 4%, respectively (<a href="#t3">Table 3</a> and Tables S2 and S3). Median hemoglobin levels after surgery were similar with milvexian and enoxaparin (Fig. S1).</div></section><section id="sec-2-5"><h3>Pharmacodynamic and Pharmacokinetic Measures</h3><div role="paragraph">Milvexian increased the activated partial-thromboplastin time ratio in a dose-dependent manner, whereas enoxaparin had no apparent effect; no evidence of a dose-dependent increase in bleeding was noted with milvexian (<a href="#f2">Figure 2</a>). Neither milvexian nor enoxaparin increased the prothrombin time ratio (Fig. S2).</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 2</div><nav><a href="#f2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f2" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f2.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/60c657c9-aa8f-46a1-98d1-8f4ca52cb264/assets/images/large/nejmoa2113194_f2.jpg" height="2474" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Activated Partial-Thromboplastin Time (aPTT) Ratios and Bleeding Incidences.</div><div class="notes"><div role="doc-footnote">Panel A shows box plots of aPTT ratios with the various doses of milvexian and with enoxaparin. The median is indicated by the horizontal line in the box; the top and bottom of the box indicate the upper and lower limits, respectively, of the interquartile range; and the vertical lines above and below the box indicate the maximum and minimum values, respectively. Panel B shows the incidences of any bleeding and clinically relevant bleeding (defined as the composite of major bleeding and clinically relevant nonmajor bleeding) according to trial group.</div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">This trial provides proof of principle that milvexian is an effective antithrombotic agent. Milvexian significantly reduced the incidence of venous thromboembolism after elective knee arthroplasty in a dose-dependent manner with both twice-daily and once-daily regimens. Furthermore, the incidence of venous thromboembolism was significantly lower with daily milvexian doses of 100 mg or more than that with enoxaparin. Although the incidence of any bleeding was 4% with both milvexian and enoxaparin, the incidence of the composite of major bleeding and clinically relevant nonmajor bleeding was low across total daily doses of milvexian that ranged from 25 to 400 mg. Therefore, postoperative factor XIa inhibition with milvexian was effective for preventing venous thromboembolism and was associated with a low risk of clinically relevant bleeding.</div><div role="paragraph">The lower incidence of venous thromboembolism and the tendency for less extensive thrombosis with higher doses of milvexian than with enoxaparin highlight the role of factor XI in the pathogenesis of venous thrombosis after surgery. This concept is supported by the observation that an antisense oligonucleotide that reduces factor XI levels and abelacimab, an antibody that binds factor XI and prevents its activation, also are more effective than enoxaparin for thromboprophylaxis after knee arthroplasty.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8" id="body-ref-r8-2" href-manipulated="true">7,8</a></sup> However, the antisense oligonucleotide and abelacimab require parenteral administration, whereas milvexian is given orally.</div><div role="paragraph">The findings with milvexian contrast with those with osocimab, an antibody that inhibits factor XIa. When administered as a single intravenous injection 12 to 24 hours after surgery, osocimab was noninferior but not superior to enoxaparin for the prevention of venous thromboembolism after knee arthroplasty.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13" id="body-ref-r13-1" href-manipulated="true" aria-label="Reference 13">13</a></sup> These divergent results may reflect differences in the extent of factor XIa inhibition. Alternatively, as a small molecule, milvexian may gain better access to factor XIa generated at sites of thrombus formation. Regardless of mechanism, the current data indicate that postoperative factor XIa inhibition with milvexian provides effective thromboprophylaxis against venous thromboembolism. Additional studies are needed to determine the efficacy of milvexian for the prevention of arterial thrombosis.</div><div role="paragraph">Milvexian treatment increased the activated partial-thromboplastin time ratio, a finding consistent with selective inhibition of factor XIa. Despite the dose-dependent increase in the activated partial-thromboplastin time ratio, no doseâresponse relationship was seen with respect to bleeding, a finding consistent with the poor correlation between the extent of prolongation of the activated partial-thromboplastin time and the propensity for bleeding in patients with congenital factor XI deficiency.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4" id="body-ref-r4-2" href-manipulated="true" aria-label="Reference 4">4</a></sup> This dissociation probably reflects the fact that factor XI activation is essential for clot formation in the activated partial-thromboplastin time assay but is mostly dispensable for hemostasis.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup></div><div role="paragraph">Some methodologic aspects of our trial require comment. First, the strength of our conclusion regarding the low incidence of clinically relevant bleeding with milvexian is limited by the modest sample. Further studies are needed to confirm the safety of milvexian alone or in combination with antiplatelet drugs. Second, the trial was open label with respect to assignment to milvexian or enoxaparin. However, to minimize bias, the trial was blinded with respect to assignment to a milvexian regimen, and all outcomes were adjudicated by a committee whose members were unaware of treatment assignments. Third, the inclusion of minimal bleeding in the principal safety outcome ensured that all suspected bleeding events were documented and centrally adjudicated. With the open-label design, however, a potential for bias in favor of enoxaparin existed because investigators might be more vigilant for bleeding with an experimental agent than with an agent that has been used for years. Because of stricter definitions, the potential for bias was lessened in the assessment of clinically relevant bleeding, the outcome most often used for safety assessment in this patient population.<sup><a href="#core-r7" role="doc-biblioref" data-xml-rid="r7 r8 r13" id="body-ref-r13-2" href-manipulated="true">7,8,13</a></sup></div><div role="paragraph">In our trial, oral milvexian reduced the risk of postoperative thromboembolism among patients undergoing knee arthroplasty in a dose-dependent manner without increasing the risk of bleeding as compared with enoxaparin. Further studies are needed to determine whether oral anticoagulants that target factor XIa can dissociate thrombosis from hemostasis.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="published/updated" role="paragraph">This article was published on November 15, 2021, at NEJM.org.</div><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by Bristol Myers Squibb and Janssen Research and Development.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2113194_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2113194/suppl_file/nejmoa2113194_protocol.pdf" download="nejmoa2113194_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2113194_protocol.pdf" data-doi="10.1056/NEJMoa2113194">Download</a></li><li>7.02 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2113194_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2113194/suppl_file/nejmoa2113194_appendix.pdf" download="nejmoa2113194_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2113194_appendix.pdf" data-doi="10.1056/NEJMoa2113194">Download</a></li><li>324.58 KB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2113194_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2113194/suppl_file/nejmoa2113194_disclosures.pdf" download="nejmoa2113194_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2113194_disclosures.pdf" data-doi="10.1056/NEJMoa2113194">Download</a></li><li>729.12 KB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2113194_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2113194/suppl_file/nejmoa2113194_data-sharing.pdf" download="nejmoa2113194_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2113194_data-sharing.pdf" data-doi="10.1056/NEJMoa2113194">Download</a></li><li>68.78 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <em>Am Heart J</em> 2017;194:132-140.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2017.08.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29223431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417602600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+trends+in+clinical+characteristics+and+oral+anticoagulation+treatment+for+patients+with+atrial+fibrillation%3A+results+from+the+GARFIELD-AF%2C+ORBIT-AF+I%2C+and+ORBIT-AF+II+registries.&amp;publication_year=2017&amp;journal=Am+Heart+J&amp;pages=132-140&amp;doi=10.1016%2Fj.ahj.2017.08.011&amp;pmid=29223431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. <em>J Am Heart Assoc</em> 2020;9(6):e014108-e014108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.119.014108" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32146898/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521353000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rates+of+potentially+inappropriate+dosing+of+direct-acting+oral+anticoagulants+and+associations+with+geriatric+conditions+among+older+patients+with+atrial+fibrillation%3A+the+SAGE-AF+study.&amp;publication_year=2020&amp;journal=J+Am+Heart+Assoc&amp;pages=e014108-e014108&amp;doi=10.1161%2FJAHA.119.014108&amp;pmid=32146898" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. <em>J Am Coll Cardiol</em> 2021;78:625-631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2021.06.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34353538/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685572800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+inhibition+to+uncouple+thrombosis+from+hemostasis%3A+JACC+review+topic+of+the+week.&amp;publication_year=2021&amp;journal=J+Am+Coll+Cardiol&amp;pages=625-631&amp;doi=10.1016%2Fj.jacc.2021.06.010&amp;pmid=34353538" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] but plays a subsidiary part in hemostasis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] but is mostly dispensable for hemostasis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Duga S, Salomon O. Congenital factor XI deficiency: an update. <em>Semin Thromb Hemost</em> 2013;39:621-631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0033-1353420" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23929304/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323637600008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Congenital+factor+XI+deficiency%3A+an+update.&amp;publication_year=2013&amp;journal=Semin+Thromb+Hemost&amp;pages=621-631&amp;doi=10.1055%2Fs-0033-1353420&amp;pmid=23929304" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] but rarely have spontaneous bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with congenital factor XI deficiency. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. <em>Thromb Haemost</em> 2011;105:269-273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1160/TH10-05-0307" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21057700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287943600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patients+with+severe+factor+XI+deficiency+have+a+reduced+incidence+of+deep-vein+thrombosis.&amp;publication_year=2011&amp;journal=Thromb+Haemost&amp;pages=269-273&amp;doi=10.1160%2FTH10-05-0307&amp;pmid=21057700" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. <em>Blood</em> 2017;129:1210-1215.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-09-742262" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28039189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397142500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+deficiency+is+associated+with+lower+risk+for+cardiovascular+and+venous+thromboembolism+events.&amp;publication_year=2017&amp;journal=Blood&amp;pages=1210-1215&amp;doi=10.1182%2Fblood-2016-09-742262&amp;pmid=28039189" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">BÃ¼ller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. <em>N Engl J Med</em> 2015;372:232-240.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2113194&amp;key=10.1056%2FNEJMoa1405760&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25482425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348119200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+antisense+oligonucleotide+for+prevention+of+venous+thrombosis.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=232-240&amp;doi=10.1056%2FNEJMoa1405760&amp;pmid=25482425" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the prevention of venous thromboembolism. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] kidney damage from the contrast material. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] thromboprophylaxis after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. <em>N Engl J Med</em> 2021;385:609-617.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2113194&amp;key=10.1056%2FNEJMoa2105872&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34297496/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000675890900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Abelacimab+for+prevention+of+venous+thromboembolism.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=609-617&amp;doi=10.1056%2FNEJMoa2105872&amp;pmid=34297496" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the prevention of venous thromboembolism. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] thromboprophylaxis after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of BMS-986177/JNJ-70033093 in participants with mild or moderate hepatic impairment compared to healthy participants. <em>Eur Heart J</em> 2020;41:Suppl 2 (<a href="https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.3371/6005220" target="_blank">https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.3371/6005220</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ehjci/ehaa946.3371" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000606106303378" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single-dose+pharmacokinetics+of+BMS-986177%2FJNJ-70033093+in+participants+with+mild+or+moderate+hepatic+impairment+compared+to+healthy+participants.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;doi=10.1093%2Fehjci%2Fehaa946.3371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. <em>J Thromb Haemost</em> 2010;8:2458-2468.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2010.04021.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20723033/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000283982000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+dose-ranging+study+evaluating+the+oral+factor+Xa+inhibitor+edoxaban+for+the+prevention+of+venous+thromboembolism+in+patients+undergoing+total+knee+arthroplasty.&amp;publication_year=2010&amp;journal=J+Thromb+Haemost&amp;pages=2458-2468&amp;doi=10.1111%2Fj.1538-7836.2010.04021.x&amp;pmid=20723033" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] kidney damage from the contrast material. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients undergoing knee arthroplasty. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Schulman S, AngerÃ¥s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <em>J Thromb Haemost</em> 2010;8:202-204.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2009.03678.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19878532/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272864200031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Definition+of+major+bleeding+in+clinical+investigations+of+antihemostatic+medicinal+products+in+surgical+patients.&amp;publication_year=2010&amp;journal=J+Thromb+Haemost&amp;pages=202-204&amp;doi=10.1111%2Fj.1538-7836.2009.03678.x&amp;pmid=19878532" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertainty using general parametric models. <em>Stat Med</em> 2014;33:1646-1661.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.6052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24302486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334028500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Model-based+dose+finding+under+model+uncertainty+using+general+parametric+models.&amp;publication_year=2014&amp;journal=Stat+Med&amp;pages=1646-1661&amp;doi=10.1002%2Fsim.6052&amp;pmid=24302486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. <em>JAMA</em> 2020;323:130-139.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.20687" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31935028/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509352900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+osocimab+in+preventing+venous+thromboembolism+among+patients+undergoing+knee+arthroplasty%3A+the+FOXTROT+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=130-139&amp;doi=10.1001%2Fjama.2019.20687&amp;pmid=31935028" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] thromboembolism after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/23"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> â¢ <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">23</span></span> â¢ <span property="datePublished">December 2, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">2161</span>-<span property="pageEnd">2172</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright Â© 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: November 15, 2021</div><div><b class="core-label">Published in issue</b>: December 2, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/anticoagulation-thromboembolism-cardiology" alt="View article keyword Anticoagulation/Thromboembolism (Cardiology)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Cardiology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/anticoagulation-thromboembolism-pulmonary-critical-care" alt="View article keyword Anticoagulation/Thromboembolism (Pulmonary/Critical Care)" data-interactiontype="article_recirculation_click">Anticoagulation/Thromboembolism (Pulmonary/Critical Care)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/coagulation" alt="View article keyword Coagulation" data-interactiontype="article_recirculation_click">Coagulation</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/orthopedics-general" alt="View article keyword Orthopedics General" data-interactiontype="article_recirculation_click">Orthopedics General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/surgery-general" alt="View article keyword Surgery General" data-interactiontype="article_recirculation_click">Surgery General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Jeffrey I.</span> <span property="familyName">Weitz</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">John</span> <span property="familyName">Strony</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Walter</span> <span property="familyName">Ageno</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">David</span> <span property="familyName">Gailani</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elaine M.</span> <span property="familyName">Hylek</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Michael R.</span> <span property="familyName">Lassen</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Kenneth W.</span> <span property="familyName">Mahaffey</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Ravi S.</span> <span property="familyName">Notani</span>, <span property="honorificSuffix">M.B.A.</span></span>, <span property="author" typeof="Person"><span property="givenName">Robin</span> <span property="familyName">Roberts</span>, <span property="honorificSuffix">M.S.</span></span>, <span property="author" typeof="Person"><span property="givenName">Annelise</span> <span property="familyName">Segers</span>, <span property="honorificSuffix">M.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Gary E.</span> <span property="familyName">Raskob</span>, <span property="honorificSuffix">Ph.D.</span></span>, for <span property="author" typeof="Person">the AXIOMATIC-TKR Investigators<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From the Thrombosis and Atherosclerosis Research Institute and McMaster University (J.I.W., R.R.) â both in Hamilton, ON, Canada; Janssen Research and Development, Raritan, NJ (J.S., R.S.N.); the University of Insubria, Varese, Italy (W.A.); Vanderbilt University Medical Center, Nashville (D.G.); Boston University School of Medicine, Boston (E.M.H.); GildhÃ¸j Private Hospital, Copenhagen (M.R.L.); Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA (K.W.M.); International Trial Expertise Advisory and Services, Amsterdam (A.S.); and Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City (G.E.R.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Dr. Weitz can be contacted at <a href="mailto:weitzj@taari.ca">weitzj@taari.ca</a> or at the Thrombosis and Atherosclerosis Research Institute, 237 Barton St. East, Hamilton, ON, Canada L8L 2X2.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">The investigators in the AXIOMATIC-TKR trial and the members of the trial committees are listed in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">188</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2113194" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="3c124fc6-f8b9-dfdb-a58f-62871b63f976"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285" style="display:inline-block;">
                <img alt="Article has an altmetric score of 282" src="https://badges.altmetric.com/?size=320&amp;score=282&amp;types=mabttwf1" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_3c124fc6-f8b9-dfdb-a58f-62871b63f976" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=news">
          Picked up by <b>29</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=blogs">
          Blogged by <b>1</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=twitter">
          Posted by <b>120</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=facebook">
          On <b>2</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=wikipedia">
          Referenced in <b>7</b> Wikipedia pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #F4006E;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=116940285&amp;tab=research-highlights">
          Highlighted by <b>1</b> platforms
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>174</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6ac5dd00901ab-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2113194"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2113194%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="188" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">C. Michael Gibson, </li><li class="list-inline-item cited-by__entry__author">M. Cecilia Bahit, </li><li class="list-inline-item cited-by__entry__author">Roxana Mehran, </li><li class="list-inline-item cited-by__entry__author">Shamir R. Mehta, </li><li class="list-inline-item cited-by__entry__author">Rasha Al Lamee, </li><li class="list-inline-item cited-by__entry__author">Shinya Goto, </li><li class="list-inline-item cited-by__entry__author">Jeffrey I. Weitz, </li><li class="list-inline-item cited-by__entry__author">Jay Horrow, </li><li class="list-inline-item cited-by__entry__author">Elliot S. Barnathan, </li><li class="list-inline-item cited-by__entry__author">Robert A. Harrington, </li><li class="list-inline-item cited-by__entry__author">Kenneth W. Mahaffey, </li><li class="list-inline-item cited-by__entry__author">Carolyn S.P. Lam, </li><li class="list-inline-item cited-by__entry__author">Karen S. Pieper, </li><li class="list-inline-item cited-by__entry__author">S. Claiborne Johnston, </li><li class="list-inline-item cited-by__entry__author">Graeme J. Hankey, </li><li class="list-inline-item cited-by__entry__author">Alexei N. Plotnikov, </li><li class="list-inline-item cited-by__entry__author">Danshi Li, </li><li class="list-inline-item cited-by__entry__author">Hsiaowei Deng, </li><li class="list-inline-item cited-by__entry__author">Philippe Gabriel Steg, </li></ul><span class="cited-by__entry__title">Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS), </span><span class="cited-by__entry__series-title">American Heart Journal, </span><span class="cited-by__entry__volume"><strong>285</strong>, </span><span class="cited-by__entry__page-range">(21-28), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ahj.2025.02.011" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ahj.2025.02.011</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ahj.2025.02.011" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Muhammad Aamir Wahab, </li><li class="list-inline-item cited-by__entry__author">Atta Ullah Khan, </li><li class="list-inline-item cited-by__entry__author">Silvia Mercadante, </li><li class="list-inline-item cited-by__entry__author">Iolanda Cafarella, </li><li class="list-inline-item cited-by__entry__author">Lorenzo Bertolino, </li><li class="list-inline-item cited-by__entry__author">Emanuele Durante-Mangoni, </li></ul><span class="cited-by__entry__title">Deciphering the Complex Relationships Between the Hemostasis System and Infective Endocarditis, </span><span class="cited-by__entry__series-title">Journal of Clinical Medicine, </span><span class="cited-by__entry__volume"><strong>14</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(3965), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/jcm14113965" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/jcm14113965</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/jcm14113965" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Andreas Verstraete, </li><li class="list-inline-item cited-by__entry__author">Quentin Van Thillo, </li><li class="list-inline-item cited-by__entry__author">Thomas Vanassche, </li><li class="list-inline-item cited-by__entry__author">Peter Verhamme, </li></ul><span class="cited-by__entry__title">New horizons in the pharmacological management of venous thromboembolism, </span><span class="cited-by__entry__series-title">HemaSphere, </span><span class="cited-by__entry__volume"><strong>9</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1002/hem3.70143" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1002/hem3.70143</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1002/hem3.70143" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ziwei Huang, </li><li class="list-inline-item cited-by__entry__author">Anirudh Buddhiraju, </li><li class="list-inline-item cited-by__entry__author">Tony Lin-Wei Chen, </li><li class="list-inline-item cited-by__entry__author">MohammadAmin RezazadehSaatlou, </li><li class="list-inline-item cited-by__entry__author">Shane Fei Chen, </li><li class="list-inline-item cited-by__entry__author">Blake M. Bacevich, </li><li class="list-inline-item cited-by__entry__author">Pengwei Xiao, </li><li class="list-inline-item cited-by__entry__author">Young-Min Kwon, </li></ul><span class="cited-by__entry__title">Machine learning models based on a national-scale cohort accurately identify patients at high risk of deep vein thrombosis following primary total hip arthroplasty, </span><span class="cited-by__entry__series-title">Orthopaedics &amp; Traumatology: Surgery &amp; Research, </span><span class="cited-by__entry__volume"><strong>111</strong>, </span><span class="cited-by__entry__issue">4, </span><span class="cited-by__entry__page-range">(104238), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.otsr.2025.104238" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.otsr.2025.104238</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.otsr.2025.104238" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Patricia Gomez-Rosas, </li><li class="list-inline-item cited-by__entry__author">Magdolna Nagy, </li><li class="list-inline-item cited-by__entry__author">Henry M.H. Spronk, </li><li class="list-inline-item cited-by__entry__author">Laura Russo, </li><li class="list-inline-item cited-by__entry__author">Sara Gamba, </li><li class="list-inline-item cited-by__entry__author">Carmen Julia Tartari, </li><li class="list-inline-item cited-by__entry__author">Silvia Bolognini, </li><li class="list-inline-item cited-by__entry__author">Chiara Ticozzi, </li><li class="list-inline-item cited-by__entry__author">Francesca Schieppati, </li><li class="list-inline-item cited-by__entry__author">Roberta Sarmiento, </li><li class="list-inline-item cited-by__entry__author">Filippo De Braud, </li><li class="list-inline-item cited-by__entry__author">Giovanna Masci, </li><li class="list-inline-item cited-by__entry__author">Carlo Tondini, </li><li class="list-inline-item cited-by__entry__author">Fausto Petrelli, </li><li class="list-inline-item cited-by__entry__author">Francesco Giuliani, </li><li class="list-inline-item cited-by__entry__author">Andrea DâAlessio, </li><li class="list-inline-item cited-by__entry__author">Armando Santoro, </li><li class="list-inline-item cited-by__entry__author">Giampietro Gasparini, </li><li class="list-inline-item cited-by__entry__author">Roberto Labianca, </li><li class="list-inline-item cited-by__entry__author">Hugo ten Cate, </li><li class="list-inline-item cited-by__entry__author">Anna Falanga, </li><li class="list-inline-item cited-by__entry__author">Marina Marchetti, </li><li class="list-inline-item cited-by__entry__author">Falanga Anna, </li><li class="list-inline-item cited-by__entry__author">Bolognini Silvia, </li><li class="list-inline-item cited-by__entry__author">Gamba Sara, </li><li class="list-inline-item cited-by__entry__author">Gomez Rosas Patricia, </li><li class="list-inline-item cited-by__entry__author">Marchetti Marina, </li><li class="list-inline-item cited-by__entry__author">Russo Laura, </li><li class="list-inline-item cited-by__entry__author">Schieppati Francesca, </li><li class="list-inline-item cited-by__entry__author">Tartari Carmen Julia, </li><li class="list-inline-item cited-by__entry__author">Ticozzi Chiara, </li><li class="list-inline-item cited-by__entry__author">Santoro Armando, </li><li class="list-inline-item cited-by__entry__author">Masci Giovanna, </li><li class="list-inline-item cited-by__entry__author">De Braud Filippo, </li><li class="list-inline-item cited-by__entry__author">Celio Luigi, </li><li class="list-inline-item cited-by__entry__author">Martinetti Antonia, </li><li class="list-inline-item cited-by__entry__author">Nichetti Federico, </li><li class="list-inline-item cited-by__entry__author">Tondini Carlo, </li><li class="list-inline-item cited-by__entry__author">Labianca Roberto, </li><li class="list-inline-item cited-by__entry__author">Gasparini Giampietro, </li><li class="list-inline-item cited-by__entry__author">Sarmiento Roberta, </li><li class="list-inline-item cited-by__entry__author">Gennaro Elisabetta, </li><li class="list-inline-item cited-by__entry__author">Minelli Mauro, </li><li class="list-inline-item cited-by__entry__author">Barni Sandro, </li><li class="list-inline-item cited-by__entry__author">Petrelli Fausto, </li><li class="list-inline-item cited-by__entry__author">Ghilardi Mara, </li><li class="list-inline-item cited-by__entry__author">DâAlessio Andrea, </li><li class="list-inline-item cited-by__entry__author">Giuliani Francesco, </li></ul><span class="cited-by__entry__title">Activated factor XIâantithrombin and thrombinâantithrombin complexes in the prediction of venous thromboembolism and mortality in patients with nonâsmall-cell lung cancer, </span><span class="cited-by__entry__series-title">Journal of Thrombosis and Haemostasis, </span><span class="cited-by__entry__volume"><strong>23</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1908-1919), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jtha.2025.02.029" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jtha.2025.02.029</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jtha.2025.02.029" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Siddharth M. Patel, </li><li class="list-inline-item cited-by__entry__author">Robert P. Giugliano, </li><li class="list-inline-item cited-by__entry__author">David A. Morrow, </li><li class="list-inline-item cited-by__entry__author">Sanobar Parkar, </li><li class="list-inline-item cited-by__entry__author">Hannah Shapiro, </li><li class="list-inline-item cited-by__entry__author">Bruce Hug, </li><li class="list-inline-item cited-by__entry__author">Julia F. Kuder, </li><li class="list-inline-item cited-by__entry__author">Erica L. Goodrich, </li><li class="list-inline-item cited-by__entry__author">Shih-Ann Chen, </li><li class="list-inline-item cited-by__entry__author">Shaun G. Goodman, </li><li class="list-inline-item cited-by__entry__author">Boyoung Joung, </li><li class="list-inline-item cited-by__entry__author">Robert G. Kiss, </li><li class="list-inline-item cited-by__entry__author">Wojciech Wojakowski, </li><li class="list-inline-item cited-by__entry__author">Jeffrey I. Weitz, </li><li class="list-inline-item cited-by__entry__author">Sabina A. Murphy, </li><li class="list-inline-item cited-by__entry__author">Stephen D. Wiviott, </li><li class="list-inline-item cited-by__entry__author">Daniel Bloomfield, </li><li class="list-inline-item cited-by__entry__author">Marc S. Sabatine, </li><li class="list-inline-item cited-by__entry__author">Christian T. Ruff, </li></ul><span class="cited-by__entry__title">Long-Acting Factor XI Inhibition and Periprocedural Bleeding, </span><span class="cited-by__entry__series-title">Journal of the American College of Cardiology, </span><span class="cited-by__entry__volume"><strong>85</strong>, </span><span class="cited-by__entry__issue">23, </span><span class="cited-by__entry__page-range">(2288-2298), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jacc.2025.04.018" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jacc.2025.04.018</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jacc.2025.04.018" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Dandan Feng, </li><li class="list-inline-item cited-by__entry__author">Jianchun Wang, </li></ul><span class="cited-by__entry__title">Factor XI inhibitors are the novel promising anticoagulants in the treatment of age related thrombotic disease, </span><span class="cited-by__entry__series-title">Frontiers in Cardiovascular Medicine, </span><span class="cited-by__entry__volume"><strong>12</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fcvm.2025.1498826" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fcvm.2025.1498826</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fcvm.2025.1498826" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Siddharth M. Patel, </li><li class="list-inline-item cited-by__entry__author">Robert P. Giugliano, </li><li class="list-inline-item cited-by__entry__author">Christian T. Ruff, </li></ul><span class="cited-by__entry__title">Factor XI Inhibition for Atrial Fibrillation: Where Do We Stand?, </span><span class="cited-by__entry__series-title">Circulation, </span><span class="cited-by__entry__volume"><strong>151</strong>, </span><span class="cited-by__entry__issue">20, </span><span class="cited-by__entry__page-range">(1433-1435), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1161/CIRCULATIONAHA.125.074100" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1161/CIRCULATIONAHA.125.074100</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1161/CIRCULATIONAHA.125.074100" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Ahmed Emara, </li><li class="list-inline-item cited-by__entry__author">Ahmed Farid Gadelmawla, </li><li class="list-inline-item cited-by__entry__author">Mohamed Emara, </li><li class="list-inline-item cited-by__entry__author">Mohamed R. Murad, </li><li class="list-inline-item cited-by__entry__author">Mohamed S. Elgendy, </li><li class="list-inline-item cited-by__entry__author">Mohamed Ellebedy, </li><li class="list-inline-item cited-by__entry__author">Lina Hemmeda, </li><li class="list-inline-item cited-by__entry__author">Mohamed A. Aldemerdash, </li><li class="list-inline-item cited-by__entry__author">Ahmed Abduljalil Mohammed, </li><li class="list-inline-item cited-by__entry__author">Basel Abdelazeem, </li></ul><span class="cited-by__entry__title">Factor XI/XIa inhibitors versus direct oral anticoagulants in atrial fibrillation with stroke risk: a GRADE-assessed meta-analysis of randomized controlled trials, </span><span class="cited-by__entry__series-title">Naunyn-Schmiedeberg's Archives of Pharmacology, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1007/s00210-025-04259-9" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1007/s00210-025-04259-9</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1007/s00210-025-04259-9" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Paolo Ossola, </li><li class="list-inline-item cited-by__entry__author">Claudio Ciampi, </li><li class="list-inline-item cited-by__entry__author">Andrea Cesari, </li><li class="list-inline-item cited-by__entry__author">Luca Villanova, </li><li class="list-inline-item cited-by__entry__author">NiccolÃ² Grieco, </li><li class="list-inline-item cited-by__entry__author">Giovanna Viola, </li><li class="list-inline-item cited-by__entry__author">Alice Sacco, </li><li class="list-inline-item cited-by__entry__author">Leonardo De Luca, </li><li class="list-inline-item cited-by__entry__author">Fabrizio Oliva, </li></ul><span class="cited-by__entry__title">Factor XI inhibitors: is it time for a paradigm shift in anticoagulation?, </span><span class="cited-by__entry__series-title">Journal of Cardiovascular Medicine, </span><span class="cited-by__entry__volume"><strong>26</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(303-311), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.2459/JCM.0000000000001735" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.2459/JCM.0000000000001735</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.2459/JCM.0000000000001735" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-23%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2113194%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2113194" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2113194" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2113194.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f1.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/a7da21f0-142e-4174-931b-00e602025cf9/assets/images/large/nejmoa2113194_f1.jpg" height="1997" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Enrollment, Randomization, and Populations for Analyses.</div><div class="notes"><div role="doc-footnote">Enrollment in the group receiving 25 mg of milvexian once daily was stopped early by the trial operations committee after an ad hoc analysis showed insufficient efficacy. A regimen of 50 mg of milvexian once daily was then added to the trial regimens. One patient who was assigned to receive 100 mg of milvexian twice daily received 50 mg twice daily, and another patient who was assigned to receive 200 mg of milvexian twice daily received 25 mg once daily. For the safety analyses, these patients were included in the actual treatment group, whereas for the efficacy analyses, they were included in the planned treatment group.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f2"><figure class="graphic"><a class="open-in-viewer" href="#f2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f2.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/60c657c9-aa8f-46a1-98d1-8f4ca52cb264/assets/images/large/nejmoa2113194_f2.jpg" height="2474" width="2640" aria-labelledby="f2" loading="lazy"></a><figcaption><div class="caption">Activated Partial-Thromboplastin Time (aPTT) Ratios and Bleeding Incidences.</div><div class="notes"><div role="doc-footnote">Panel A shows box plots of aPTT ratios with the various doses of milvexian and with enoxaparin. The median is indicated by the horizontal line in the box; the top and bottom of the box indicate the upper and lower limits, respectively, of the interquartile range; and the vertical lines above and below the box indicate the maximum and minimum values, respectively. Panel B shows the incidences of any bleeding and clinically relevant bleeding (defined as the composite of major bleeding and clinically relevant nonmajor bleeding) according to trial group.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f2"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f2" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2113194/asset/2b7d5093-0f12-4547-bdb5-5cb0a3a70fa0/assets/images/large/nejmoa2113194_t1.jpg" height="3438" width="1804" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<a href="#core-t1fn2" role="doc-noteref">â </a></th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg</th><th class="xxxx-borders">50 mg</th><th class="xxxx-borders">100 mg</th><th class="xxxx-borders">200 mg</th><th class="xxxx-borders">25 mg</th><th class="xxxx-borders">50 mg</th><th class="xxxx-borders">200 mg</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Modified intention-to-treat population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">129</td><td class="xxxx-borders">124</td><td class="xxxx-borders">134</td><td class="xxxx-borders">131</td><td class="xxxx-borders">28</td><td class="xxxx-borders">127</td><td class="xxxx-borders">123</td><td class="xxxr-borders">252</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Age â yr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">69</td><td class="xxxx-borders">68</td><td class="xxxx-borders">67</td><td class="xxxx-borders">69</td><td class="xxxx-borders">67</td><td class="xxxx-borders">68</td><td class="xxxx-borders">68</td><td class="xxxr-borders">68</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">51â87</td><td class="xxxx-borders shading">51â87</td><td class="xxxx-borders shading">50â86</td><td class="xxxx-borders shading">50â86</td><td class="xxxx-borders shading">55â77</td><td class="xxxx-borders shading">50â88</td><td class="xxxx-borders shading">50â88</td><td class="xxxr-borders shading">50â90</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Female sex â no. (%)</td><td class="xxxx-borders">92 (71)</td><td class="xxxx-borders">89 (72)</td><td class="xxxx-borders">88 (66)</td><td class="xxxx-borders">89 (68)</td><td class="xxxx-borders">18 (64)</td><td class="xxxx-borders">92 (72)</td><td class="xxxx-borders">88 (72)</td><td class="xxxr-borders">171 (68)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Race â no. (%)<a href="#core-t1fn3" role="doc-noteref">â¡</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">White</td><td class="xxxx-borders">112 (87)</td><td class="xxxx-borders">107 (86)</td><td class="xxxx-borders">117 (87)</td><td class="xxxx-borders">116 (89)</td><td class="xxxx-borders">28 (100)</td><td class="xxxx-borders">103 (81)</td><td class="xxxx-borders">105 (85)</td><td class="xxxr-borders">216 (86)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Asian</td><td class="xxxx-borders shading">16 (12)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxx-borders shading">14 (10)</td><td class="xxxx-borders shading">14 (11)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">21 (17)</td><td class="xxxx-borders shading">15 (12)</td><td class="xxxr-borders shading">29 (12)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Black</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">3 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Other</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">3 (2)</td><td class="xxxr-borders shading">2 (1)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Weight â kg</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">83</td><td class="xxxx-borders shading">79</td><td class="xxxx-borders shading">85</td><td class="xxxx-borders shading">84</td><td class="xxxx-borders shading">82</td><td class="xxxx-borders shading">80</td><td class="xxxx-borders shading">82</td><td class="xxxr-borders shading">81</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">40â150</td><td class="xxxx-borders">44â150</td><td class="xxxx-borders">48â130</td><td class="xxxx-borders">42â132</td><td class="xxxx-borders">56â134</td><td class="xxxx-borders">48â181</td><td class="xxxx-borders">48â129</td><td class="xxxr-borders">41â146</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Baseline creatinine clearance â ml/min<a href="#core-t1fn4" role="doc-noteref">Â§</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">86</td><td class="xxxx-borders">92</td><td class="xxxx-borders">90</td><td class="xxxx-borders">94</td><td class="xxxx-borders">95</td><td class="xxxx-borders">88</td><td class="xxxx-borders">91</td><td class="xxxr-borders">92</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">71â109</td><td class="xxxx-borders shading">75â113</td><td class="xxxx-borders shading">70â118</td><td class="xxxx-borders shading">70â114</td><td class="xxxx-borders shading">72â127</td><td class="xxxx-borders shading">70â105</td><td class="xxxx-borders shading">73â115</td><td class="xxxr-borders shading">72â114</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Preoperative enoxaparin â no. (%)</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">9 (7)</td><td class="xxxx-borders">8 (6)</td><td class="xxxx-borders">7 (5)</td><td class="xxxx-borders">2 (7)</td><td class="xxxx-borders">10 (8)</td><td class="xxxx-borders">11 (9)</td><td class="xxxr-borders">28 (11)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Type of anesthesia â no. (%)<a href="#core-t1fn5" role="doc-noteref">Â¶</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">General</td><td class="xxxx-borders">29 (22)</td><td class="xxxx-borders">25 (20)</td><td class="xxxx-borders">31 (23)</td><td class="xxxx-borders">34 (26)</td><td class="xxxx-borders">5 (18)</td><td class="xxxx-borders">29 (23)</td><td class="xxxx-borders">26 (21)</td><td class="xxxr-borders">57 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Spinal</td><td class="xxxx-borders shading">99 (77)</td><td class="xxxx-borders shading">99 (80)</td><td class="xxxx-borders shading">102 (76)</td><td class="xxxx-borders shading">96 (73)</td><td class="xxxx-borders shading">23 (82)</td><td class="xxxx-borders shading">101 (80)</td><td class="xxxx-borders shading">99 (80)</td><td class="xxxr-borders shading">194 (77)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Epidural</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">5 (4)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">6 (5)</td><td class="xxxx-borders">3 (2)</td><td class="xxxr-borders">7 (3)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Regional</td><td class="xxxx-borders shading">20 (16)</td><td class="xxxx-borders shading">33 (27)</td><td class="xxxx-borders shading">42 (31)</td><td class="xxxx-borders shading">33 (25)</td><td class="xxxx-borders shading">6 (21)</td><td class="xxxx-borders shading">33 (26)</td><td class="xxxx-borders shading">29 (24)</td><td class="xxxr-borders shading">58 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Other</td><td class="xxxx-borders">2 (2)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">3 (2)</td><td class="xxxx-borders">4 (3)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">4 (3)</td><td class="xxxr-borders">9 (4)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Duration of surgery â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxx-borders">1.4</td><td class="xxxr-borders">1.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">0.5â3.5</td><td class="xxxx-borders shading">0.7â3.1</td><td class="xxxx-borders shading">0.5â6.6</td><td class="xxxx-borders shading">0.6â2.8</td><td class="xxxx-borders shading">0.8â2.8</td><td class="xxxx-borders shading">0.6â3.3</td><td class="xxxx-borders shading">0.7â3.5</td><td class="xxxr-borders shading">0.4â3.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Tourniquet use â no. (%)</td><td class="xxxx-borders">89 (69)</td><td class="xxxx-borders">88 (71)</td><td class="xxxx-borders">98 (73)</td><td class="xxxx-borders">84 (64)</td><td class="xxxx-borders">20 (71)</td><td class="xxxx-borders">93 (73)</td><td class="xxxx-borders">84 (68)</td><td class="xxxr-borders">188 (75)</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Duration of tourniquet use â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.1</td><td class="xxxx-borders">1.3</td><td class="xxxx-borders">1.2</td><td class="xxxx-borders">1.3</td><td class="xxxr-borders">1.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">0.3â15</td><td class="xxxx-borders shading">0.2â23</td><td class="xxxx-borders shading">0.3â10</td><td class="xxxx-borders shading">0.4â10</td><td class="xxxx-borders shading">0.2â19</td><td class="xxxx-borders shading">0.3â20</td><td class="xxxx-borders shading">0.3â15</td><td class="xxxr-borders shading">0.2â15</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Time after surgery to ambulation â days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">1</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Range</td><td class="xxxx-borders">0â3</td><td class="xxxx-borders">0â3</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0Ì«â4</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0â4</td><td class="xxxx-borders">0â6</td><td class="xxxr-borders">0â4</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Baseline factor XI clotting activity â %<a href="#core-t1fn6" role="doc-noteref">â</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">109</td><td class="xxxx-borders">107</td><td class="xxxx-borders">104</td><td class="xxxx-borders">110</td><td class="xxxx-borders">107</td><td class="xxxx-borders">100</td><td class="xxxx-borders">102</td><td class="xxxr-borders">114</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Interquartile range</td><td class="xxxx-borders shading">94â127</td><td class="xxxx-borders shading">91â119</td><td class="xxxx-borders shading">93â119</td><td class="xxxx-borders shading">95â124</td><td class="xxxx-borders shading">89â116</td><td class="xxxx-borders shading">87â117</td><td class="xxxx-borders shading">87â113</td><td class="xxxr-borders shading">100â131</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Baseline activated partial-thromboplastin time â sec<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">27</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">26</td><td class="xxxr-borders shading">26</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Interquartile range</td><td class="xxxx-borders">24â28</td><td class="xxxx-borders">25â29</td><td class="xxxx-borders">25â28</td><td class="xxxx-borders">24â28</td><td class="xxxx-borders">25â28</td><td class="xxxx-borders">25â29</td><td class="xxxx-borders">25â28</td><td class="xxxr-borders">25â28</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Safety population</b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">No. of patients</td><td class="xxxx-borders">148</td><td class="xxxx-borders">148</td><td class="xxxx-borders">149</td><td class="xxxx-borders">148</td><td class="xxxx-borders">33</td><td class="xxxx-borders">150</td><td class="xxxx-borders">147</td><td class="xxxr-borders">296</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Time after surgery to milvexian or enoxaparin administration â hr</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Median</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">22</td><td class="xxxx-borders">23</td><td class="xxxr-borders">22</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Range</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">13â25</td><td class="xxxx-borders shading">12â26</td><td class="xxxx-borders shading">13â25</td><td class="xxxx-borders shading">13â26</td><td class="xxxx-borders shading">14â26</td><td class="xxxr-borders shading">7â34</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Duration of milvexian or enoxaparin treatment â days</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Median</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">12</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">12</td><td class="xxxr-borders shading">12</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12" data-xml-align="left">Range</td><td class="xbxx-borders">1â16</td><td class="xbxx-borders">2â16</td><td class="xbxx-borders">4â17</td><td class="xbxx-borders">4â16</td><td class="xbxx-borders">9â14</td><td class="xbxx-borders">6â16</td><td class="xbxx-borders">1â16</td><td class="xbxr-borders">1â15</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">The modified intention-to-treat population included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. The safety population included all the patients who had received at least one dose of a trial medication. Percentages may not total 100 because of rounding.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Enoxaparin was administered subcutaneously at a dose of 40 mg once daily.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Race was reported by the patient. Three patients in the group receiving 50 mg of milvexian once daily and two in the enoxaparin group chose not to report information on race.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Creatinine clearance values were calculated with the use of the Cockcroft and Gault equation.</div></div><div role="doc-footnote" data-has="label"><div class="label">Â¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Patients may have undergone more than one type of anesthesia.</div></div><div role="doc-footnote" data-has="label"><div class="label">â</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">The normal range for factor XI clotting activity is 60 to 150%.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">The normal range for the activated partial-thromboplastin time is 22 to 29 seconds.</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients.<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2113194/asset/d208a498-1156-4944-a682-5b3c7503d556/assets/images/large/nejmoa2113194_t2.jpg" height="1573" width="2615" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<br>(N=252)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg<br>(N=129)</th><th class="xxxx-borders">50 mg<br>(N=124)</th><th class="xxxx-borders">100 mg<br>(N=134)</th><th class="xxxx-borders">200 mg<br>(N=131)</th><th class="xxxx-borders">25 mg<br>(N=28)</th><th class="xxxx-borders">50 mg<br>(N=127)</th><th class="xxxx-borders">200 mg<br>(N=123)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging02 shading"><b>Primary efficacy outcome: venous thromboembolism<a href="#core-t2fn2" role="doc-noteref">â </a></b></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Any event â no. (%)</td><td class="xxxx-borders">27 (21)</td><td class="xxxx-borders">14 (11)</td><td class="xxxx-borders">12 (9)</td><td class="xxxx-borders">10 (8)</td><td class="xxxx-borders">7 (25)</td><td class="xxxx-borders">30 (24)</td><td class="xxxx-borders">8 (7)</td><td class="xxxr-borders">54 (21)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders shading">0.97 <br>(0.65â1.45)</td><td class="xxxx-borders shading">0.53 <br>(0.31â0.90)</td><td class="xxxx-borders shading">0.42 <br>(0.23â0.76)</td><td class="xxxx-borders shading">0.37 <br>(0.19â0.69)</td><td class="xxxx-borders shading">1.00 <br>(0.51â1.97)</td><td class="xxxx-borders shading">1.15 <br>(0.78â1.70)</td><td class="xxxx-borders shading">0.30 <br>(0.15â0.62)</td><td class="xxxr-borders shading">â</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Components of the primary efficacy outcome â no.<a href="#core-t2fn3" role="doc-noteref">â¡</a></b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Death from any cause</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Nonfatal pulmonary embolism</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Symptomatic distal deep-vein thrombosis</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Asymptomatic proximal deep-vein thrombosis</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Asymptomatic distal deep-vein thrombosis</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">13</td><td class="xxxx-borders shading">9</td><td class="xxxx-borders shading">10</td><td class="xxxx-borders shading">7</td><td class="xxxx-borders shading">26</td><td class="xxxx-borders shading">8</td><td class="xxxr-borders shading">50</td></tr><tr data-type="row"><td class="xxlx-borders hanging02"><b>Extent of deep-vein thrombosis on venography â no.</b></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Confluent distal into proximal</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02">Isolated proximal</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12 shading" data-xml-align="left">Large: â¥10 cm</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Small: &lt;10 cm</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1</td></tr><tr data-type="row"><td class="xxlx-borders hanging02 shading">Isolated distal</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Extensive: â¥2 veins</td><td class="xxxx-borders">9</td><td class="xxxx-borders">5</td><td class="xxxx-borders">1</td><td class="xxxx-borders">2</td><td class="xxxx-borders">5</td><td class="xxxx-borders">9</td><td class="xxxx-borders">1</td><td class="xxxr-borders">20</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging12 shading" data-xml-align="left">Limited: &lt;2 veins</td><td class="xbxx-borders shading">17</td><td class="xbxx-borders shading">8</td><td class="xbxx-borders shading">9</td><td class="xbxx-borders shading">8</td><td class="xbxx-borders shading">2</td><td class="xbxx-borders shading">18</td><td class="xbxx-borders shading">7</td><td class="xbxr-borders shading">30</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">Efficacy outcomes were assessed in the modified intention-to-treat population, which included all the patients who had received at least one dose of a trial medication and had a venogram within the prespecified time window that could be evaluated, a documented symptomatic venous thromboembolic event, or a fatal event. CI denotes confidence interval.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Venous thromboembolism was a composite of asymptomatic deep-vein thrombosis (detected by mandatory unilateral venography performed 10 to 14 days after surgery), confirmed symptomatic venous thromboembolism (symptomatic deep-vein thrombosis of the leg or nonfatal pulmonary embolism), or death from any cause.</div></div><div role="doc-footnote" data-has="label"><div class="label">â¡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">There were no cases of symptomatic proximal deep-vein thrombosis.</div></div></div></figcaption></a><figcaption><div class="caption">Efficacy Outcomes.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2113194/asset/36d3dc25-a77e-46eb-ba77-cc40bcdf0a88/assets/images/large/nejmoa2113194_t3.jpg" height="1150" width="2616" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Outcome</th><th class="txxx-borders" colspan="4"><span>Milvexian Twice Daily</span></th><th class="txxx-borders" colspan="3"><span>Milvexian Once Daily</span></th><th class="txxr-borders">Enoxaparin<br>(N=296)</th></tr><tr class="head2" data-type="row head2"><td class="xxlx-borders">&nbsp;</td><th class="xxxx-borders">25 mg<br>(N=148)</th><th class="xxxx-borders">50 mg<br>(N=148)</th><th class="xxxx-borders">100 mg<br>(N=149)</th><th class="xxxx-borders">200 mg<br>(N=148)</th><th class="xxxx-borders">25 mg<br>(N=33)</th><th class="xxxx-borders">50 mg<br>(N=150)</th><th class="xxxx-borders">200 mg<br>(N=147)</th><td class="xxxr-borders">&nbsp;</td></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Any bleeding â no. (%)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">7 (5)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">8 (5)</td><td class="xxxx-borders shading">9 (6)</td><td class="xxxr-borders shading">12 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders">0.33 <br>(0.08â1.43)</td><td class="xxxx-borders">1.15 <br>(0.47â2.82)</td><td class="xxxx-borders">1.14 <br>(0.47â2.80)</td><td class="xxxx-borders">0.81 <br>(0.29â2.24)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">1.17 <br>(0.50â2.72)</td><td class="xxxx-borders">1.51 <br>(0.66â3.43)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major bleeding or clinically relevant nonmajor bleeding â no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">5 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging12" data-xml-align="left">Relative risk vs. enoxaparin (95% CI)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">0.79 <br>(0.16â3.96)</td><td class="xxxx-borders">0.39 <br>(0.05â3.30)</td><td class="xxxx-borders">0.39 <br>(0.05â3.28)</td><td class="xxxx-borders">0<br>(NA)</td><td class="xxxx-borders">0.68 <br>(0.14â3.39)</td><td class="xxxx-borders">0.40 <br>(0.05â3.34)</td><td class="xxxr-borders">â</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Major bleeding â no. (%)</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (&lt;1)<a href="#core-t3fn2" role="doc-noteref">â </a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">Clinically relevant nonmajor bleeding â no. (%)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxx-borders">2 (1)</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">4 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02 shading" data-xml-align="left">Serious adverse event â no. (%)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">5 (3)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">1 (3)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxx-borders shading">2 (1)</td><td class="xxxr-borders shading">11 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging02" data-xml-align="left">At least one adverse event â no. (%)</td><td class="xxxx-borders">56 (38)</td><td class="xxxx-borders">67 (45)</td><td class="xxxx-borders">51 (34)</td><td class="xxxx-borders">54 (36)</td><td class="xxxx-borders">7 (21)</td><td class="xxxx-borders">58 (39)</td><td class="xxxx-borders">65 (44)</td><td class="xxxr-borders">113 (38)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging02 shading" data-xml-align="left">Adverse event leading to discontinuation of treatment â no. (%)</td><td class="xbxx-borders shading">2 (1)</td><td class="xbxx-borders shading">7 (5)</td><td class="xbxx-borders shading">2 (1)</td><td class="xbxx-borders shading">4 (3)</td><td class="xbxx-borders shading">0</td><td class="xbxx-borders shading">4 (3)</td><td class="xbxx-borders shading">6 (4)</td><td class="xbxr-borders shading">8 (3)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">Safety outcomes were assessed in the safety population, which included all the patients who had received at least one dose of a trial medication; the time for analysis included the period during which a trial medication was administered plus 2 days. NA denotes not applicable.</div></div><div role="doc-footnote" data-has="label"><div class="label">â </div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">The patient had a spontaneous subdural hematoma with decreased level of consciousness.</div></div></div></figcaption></a><figcaption><div class="caption">Safety Outcomes.<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2113194_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2113194</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Steinberg BA, Gao H, Shrader P, et al. International trends in clinical characteristics and oral anticoagulation treatment for patients with atrial fibrillation: results from the GARFIELD-AF, ORBIT-AF I, and ORBIT-AF II registries. <em>Am Heart J</em> 2017;194:132-140.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.ahj.2017.08.011" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29223431/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000417602600015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=International+trends+in+clinical+characteristics+and+oral+anticoagulation+treatment+for+patients+with+atrial+fibrillation%3A+results+from+the+GARFIELD-AF%2C+ORBIT-AF+I%2C+and+ORBIT-AF+II+registries.&amp;publication_year=2017&amp;journal=Am+Heart+J&amp;pages=132-140&amp;doi=10.1016%2Fj.ahj.2017.08.011&amp;pmid=29223431" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Sanghai S, Wong C, Wang Z, et al. Rates of potentially inappropriate dosing of direct-acting oral anticoagulants and associations with geriatric conditions among older patients with atrial fibrillation: the SAGE-AF study. <em>J Am Heart Assoc</em> 2020;9(6):e014108-e014108.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r2"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1161/JAHA.119.014108" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32146898/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000521353000026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Rates+of+potentially+inappropriate+dosing+of+direct-acting+oral+anticoagulants+and+associations+with+geriatric+conditions+among+older+patients+with+atrial+fibrillation%3A+the+SAGE-AF+study.&amp;publication_year=2020&amp;journal=J+Am+Heart+Assoc&amp;pages=e014108-e014108&amp;doi=10.1161%2FJAHA.119.014108&amp;pmid=32146898" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Hsu C, Hutt E, Bloomfield DM, Gailani D, Weitz JI. Factor XI inhibition to uncouple thrombosis from hemostasis: JACC review topic of the week. <em>J Am Coll Cardiol</em> 2021;78:625-631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jacc.2021.06.010" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34353538/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000685572800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+inhibition+to+uncouple+thrombosis+from+hemostasis%3A+JACC+review+topic+of+the+week.&amp;publication_year=2021&amp;journal=J+Am+Coll+Cardiol&amp;pages=625-631&amp;doi=10.1016%2Fj.jacc.2021.06.010&amp;pmid=34353538" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] but plays a subsidiary part in hemostasis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] but is mostly dispensable for hemostasis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Duga S, Salomon O. Congenital factor XI deficiency: an update. <em>Semin Thromb Hemost</em> 2013;39:621-631.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r4-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1055/s-0033-1353420" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/23929304/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000323637600008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Congenital+factor+XI+deficiency%3A+an+update.&amp;publication_year=2013&amp;journal=Semin+Thromb+Hemost&amp;pages=621-631&amp;doi=10.1055%2Fs-0033-1353420&amp;pmid=23929304" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r4-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r6" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] but rarely have spontaneous bleeding. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r4-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with congenital factor XI deficiency. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A, Seligsohn U. Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. <em>Thromb Haemost</em> 2011;105:269-273.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1160/TH10-05-0307" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/21057700/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000287943600010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Patients+with+severe+factor+XI+deficiency+have+a+reduced+incidence+of+deep-vein+thrombosis.&amp;publication_year=2011&amp;journal=Thromb+Haemost&amp;pages=269-273&amp;doi=10.1160%2FTH10-05-0307&amp;pmid=21057700" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Preis M, Hirsch J, Kotler A, et al. Factor XI deficiency is associated with lower risk for cardiovascular and venous thromboembolism events. <em>Blood</em> 2017;129:1210-1215.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r6"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1182/blood-2016-09-742262" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28039189/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000397142500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+deficiency+is+associated+with+lower+risk+for+cardiovascular+and+venous+thromboembolism+events.&amp;publication_year=2017&amp;journal=Blood&amp;pages=1210-1215&amp;doi=10.1182%2Fblood-2016-09-742262&amp;pmid=28039189" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">BÃ¼ller HR, Bethune C, Bhanot S, et al. Factor XI antisense oligonucleotide for prevention of venous thrombosis. <em>N Engl J Med</em> 2015;372:232-240.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r7-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_8_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2113194&amp;key=10.1056%2FNEJMoa1405760&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/25482425/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000348119200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Factor+XI+antisense+oligonucleotide+for+prevention+of+venous+thrombosis.&amp;publication_year=2015&amp;journal=N+Engl+J+Med&amp;pages=232-240&amp;doi=10.1056%2FNEJMoa1405760&amp;pmid=25482425" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r7-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the prevention of venous thromboembolism. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] kidney damage from the contrast material. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] thromboprophylaxis after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Verhamme P, Yi BA, Segers A, et al. Abelacimab for prevention of venous thromboembolism. <em>N Engl J Med</em> 2021;385:609-617.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_4_9_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2113194&amp;key=10.1056%2FNEJMoa2105872&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/34297496/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000675890900001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Abelacimab+for+prevention+of+venous+thromboembolism.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=609-617&amp;doi=10.1056%2FNEJMoa2105872&amp;pmid=34297496" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] the prevention of venous thromboembolism. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] thromboprophylaxis after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Perera V, Abelian G, Li D, et al. Single-dose pharmacokinetics of BMS-986177/JNJ-70033093 in participants with mild or moderate hepatic impairment compared to healthy participants. <em>Eur Heart J</em> 2020;41:Suppl 2 (<a href="https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.3371/6005220" target="_blank">https://academic.oup.com/eurheartj/article/41/Supplement_2/ehaa946.3371/6005220</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1093/ehjci/ehaa946.3371" target="_blank">Crossref</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000606106303378" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Single-dose+pharmacokinetics+of+BMS-986177%2FJNJ-70033093+in+participants+with+mild+or+moderate+hepatic+impairment+compared+to+healthy+participants.&amp;publication_year=2020&amp;journal=Eur+Heart+J&amp;doi=10.1093%2Fehjci%2Fehaa946.3371" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. <em>J Thromb Haemost</em> 2010;8:2458-2468.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2010.04021.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20723033/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000283982000015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+dose-ranging+study+evaluating+the+oral+factor+Xa+inhibitor+edoxaban+for+the+prevention+of+venous+thromboembolism+in+patients+undergoing+total+knee+arthroplasty.&amp;publication_year=2010&amp;journal=J+Thromb+Haemost&amp;pages=2458-2468&amp;doi=10.1111%2Fj.1538-7836.2010.04021.x&amp;pmid=20723033" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] kidney damage from the contrast material. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] in patients undergoing knee arthroplasty. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Schulman S, AngerÃ¥s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. <em>J Thromb Haemost</em> 2010;8:202-204.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1538-7836.2009.03678.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19878532/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272864200031" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Definition+of+major+bleeding+in+clinical+investigations+of+antihemostatic+medicinal+products+in+surgical+patients.&amp;publication_year=2010&amp;journal=J+Thromb+Haemost&amp;pages=202-204&amp;doi=10.1111%2Fj.1538-7836.2009.03678.x&amp;pmid=19878532" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Pinheiro J, Bornkamp B, Glimm E, Bretz F. Model-based dose finding under model uncertainty using general parametric models. <em>Stat Med</em> 2014;33:1646-1661.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/sim.6052" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24302486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000334028500002" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Model-based+dose+finding+under+model+uncertainty+using+general+parametric+models.&amp;publication_year=2014&amp;journal=Stat+Med&amp;pages=1646-1661&amp;doi=10.1002%2Fsim.6052&amp;pmid=24302486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Weitz JI, Bauersachs R, Becker B, et al. Effect of osocimab in preventing venous thromboembolism among patients undergoing knee arthroplasty: the FOXTROT randomized clinical trial. <em>JAMA</em> 2020;323:130-139.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jama.2019.20687" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31935028/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000509352900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Effect+of+osocimab+in+preventing+venous+thromboembolism+among+patients+undergoing+knee+arthroplasty%3A+the+FOXTROT+randomized+clinical+trial.&amp;publication_year=2020&amp;journal=JAMA&amp;pages=130-139&amp;doi=10.1001%2Fjama.2019.20687&amp;pmid=31935028" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r13-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] thromboembolism after knee arthroplasty. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r13-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] assessment in this patient population. </span></a></li></ul></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Salem, Massachusetts</span></div><div><span>Critical Care Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886902/critical-care-physician-salem-ma/?query=fjwp&amp;rid=428606">Critical Care Physician, Salem, MA</a></div></div><div class="nejm-widget_item"><div><span> New York</span></div><div><span>Radiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/710590/radiologist-with-clinical-informatics-interest-onsite-remote/?query=fjwp&amp;rid=3059">Radiologist with Clinical Informatics Interest - Onsite/Remote</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889047/physician-internal-medicine-hospitalist/?query=fjwf&amp;rid=385607">Physician - Internal Medicine Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Vancouver, Washington State</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/891151/internal-medicine-physician/?query=fjwf&amp;rid=14710">Internal Medicine Physician</a></div></div><div class="nejm-widget_item"><div><span> Connecticut</span></div><div><span>Surgery, Orthopedic</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/890848/orthopedic-spine-position-in-southwestern-connecticut-partnership-track/?query=fjwf&amp;rid=5127">Orthopedic Spine Position in Southwestern Connecticut - Partnership Track</a></div></div><div class="nejm-widget_item"><div><span> Mountain View, California</span></div><div><span>Obstetrics &amp; Gynecology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889135/physician-obstetrics-gynecology-mountain-view-ca-/?query=fjwf&amp;rid=845671">Physician, Obstetrics-Gynecology (Mountain View, CA)</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128720&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejmai%2Fregister%2Faifallpdf24%3Fpromo%3DOAFQF4NA%26query%3Dcm-rr%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Daifallpdf24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2113194&amp;pubId=41290555&amp;placeholderId=101337&amp;productId=1007" target="_blank"><img src="/sda/128720/NEJ-AI-Fall24-300x250---002.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6ac5dd00901ab-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6ac5dd00901ab-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6ac5dd00901ab-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$901131255$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$901131255$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$901131255$--></div></div><div class="mlt-body"><!--?lit$901131255$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$901131255$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$901131255$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901131255$-->Aug 12, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2105872?query=recirc_Semantic" target="_self">Abelacimab for Prevention of Venous Thromboembolism</a></div><div class="mlt-article-authors"><!--?lit$901131255$-->P. Verhamme and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm-evidence" href="https://evidence.nejm.org/browse/nejm-article-type/original-article?query=recirc_Semantic" target="_self"><!--?lit$901131255$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$901131255$-->NEJM Evidence</span> <span class="mlt-article-pubdate"><!--?lit$901131255$-->Jun 27, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200332?query=recirc_Semantic" target="_self">Enoxaparin versus Placebo to Prevent Symptomatic Venous Thromboembolism in Hospitalized Older Adult Medical Patients</a></div><div class="mlt-article-authors"><!--?lit$901131255$-->D. Mottier and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$901131255$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$901131255$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901131255$-->Apr 10, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2416112?query=recirc_Semantic" target="_self">Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism</a></div><div class="mlt-article-authors"><!--?lit$901131255$-->I. MahÃ© and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$901131255$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$901131255$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901131255$-->Nov 04, 2021</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2114895?query=recirc_Semantic" target="_self">Abelacimab for Prevention of Venous Thromboembolism</a></div><div class="mlt-article-authors"><!--?lit$901131255$--></div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/correspondence" target="_self"><!--?lit$901131255$-->Correspondence</a> <span class="mlt-article-site-label"><!--?lit$901131255$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$901131255$-->Apr 02, 2020</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMc2001365?query=recirc_Semantic" target="_self">More on Venous Thrombosis during Spaceflight</a></div><div class="mlt-article-authors"><!--?lit$901131255$--></div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2113194?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2113194" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2113194.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2113194"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">Milvexian for the Prevention of Venous Thromboembolism</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMoa2111016" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2108163" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f1.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/a7da21f0-142e-4174-931b-00e602025cf9/assets/images/large/nejmoa2113194_f1.jpg" height="1997" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Enrollment, Randomization, and Populations for Analyses.</div><div class="notes"><div role="doc-footnote">Enrollment in the group receiving 25 mg of milvexian once daily was stopped early by the trial operations committee after an ad hoc analysis showed insufficient efficacy. A regimen of 50 mg of milvexian once daily was then added to the trial regimens. One patient who was assigned to receive 100 mg of milvexian twice daily received 50 mg twice daily, and another patient who was assigned to receive 200 mg of milvexian twice daily received 25 mg once daily. For the safety analyses, these patients were included in the actual treatment group, whereas for the efficacy analyses, they were included in the planned treatment group.</div></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f2" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2113194_f2.jpg"><img src="/cms/10.1056/NEJMoa2113194/asset/60c657c9-aa8f-46a1-98d1-8f4ca52cb264/assets/images/large/nejmoa2113194_f2.jpg" height="2474" width="2640" aria-labelledby="f2" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 2</div><div class="fv__item__description"><figcaption><div class="caption">Activated Partial-Thromboplastin Time (aPTT) Ratios and Bleeding Incidences.</div><div class="notes"><div role="doc-footnote">Panel A shows box plots of aPTT ratios with the various doses of milvexian and with enoxaparin. The median is indicated by the horizontal line in the box; the top and bottom of the box indicate the upper and lower limits, respectively, of the interquartile range; and the vertical lines above and below the box indicate the maximum and minimum values, respectively. Panel B shows the incidences of any bleeding and clinically relevant bleeding (defined as the composite of major bleeding and clinically relevant nonmajor bleeding) according to trial group.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients.<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Efficacy Outcomes.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Safety Outcomes.<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/23" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 23</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 02, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2103294" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">P. Harter and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 02, 2021</span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2109730" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D. Mevorach and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Dec 02, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li data-toggle="tooltip" data-original-title="Visual Abstract" class="issue-item_meta-item"><span role="img" aria-label="Visual Abstract" tabindex="0" class="issue-item_visualAbstract"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-visual"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2108163" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">D.M. Weinreich and Others</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2113194%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2113194&amp;pubId=41290555&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2113194%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2113194&amp;pubId=41290555&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright Â© 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id05624126239310586" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6ac5dd00901ab-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6ac5dd00901ab-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6ac5dd00901ab-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6ac5dd00901ab-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6ac5dd00901ab-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6ac5dd00901ab-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6ac5dd00901ab-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6ac5dd00901ab-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6ac5dd00901ab-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6ac5dd00901ab-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6ac5dc98701ab',t:'MTc0OTUzNTQ4Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6ac5dc98701ab&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><iframe name="captureIFrame_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-transactionid="at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" id="captureIFrame_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" target="captureIFrame_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="â" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="capture_screen"><input id="capture_signIn_js_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="js_version"><input id="capture_signIn_transactionId_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" type="hidden" class="capture_transactionId_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="capture_transactionId"><input id="capture_signIn_form_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="form"><input id="capture_signIn_flow_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="flow"><input id="capture_signIn_client_id_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="client_id"><input id="capture_signIn_redirect_uri_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="redirect_uri"><input id="capture_signIn_response_type_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="response_type"><input id="capture_signIn_flow_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="flow_version"><input id="capture_signIn_settings_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="settings_version"><input id="capture_signIn_locale_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="locale"><input id="capture_signIn_recaptcha_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_at3u05fvzf7xke7iofymfd04xmwi5xr79yhvfhee" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div><div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">â</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">Moreâ¦</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><uha-nmosdtyuosle></uha-nmosdtyuosle><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2113194?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=3-10"></script></body></html>